PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34676048-6	2021	The TAK1-inhibitors NG25 and 5Z-7-oxozeaenol (5Z-7) were cytotoxic to MM cell lines and patient cells.	5-7-oxo-zeaenol	29-44	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	4-8
34717002-9	2021	Treatment with the TAK1 inhibitor 5Z-7-oxozeaenol abrogated breviscapine-mediated hepatoprotection under metabolic stress.	5-7-oxo-zeaenol	34-49	mitogen-activated protein kinase kinase kinase 7	Mus musculus	19-23
34976206-4	2022	Methods: Angiogenic activities were assessed in ex vivo and in vitro models subjected to TAK1 inhibition by 5Z-7-oxozeaenol, a selective inhibitor of TAK1.	5-7-oxo-zeaenol	108-123	mitogen-activated protein kinase kinase kinase 7	Mus musculus	89-93
34504651-0	2021	Inhibition of the MAP2K7-JNK pathway with 5Z-7-oxozeaenol induces apoptosis in T-cell acute lymphoblastic leukemia.	5-7-oxo-zeaenol	42-57	mitogen-activated protein kinase kinase 7	Homo sapiens	18-24
34504651-0	2021	Inhibition of the MAP2K7-JNK pathway with 5Z-7-oxozeaenol induces apoptosis in T-cell acute lymphoblastic leukemia.	5-7-oxo-zeaenol	42-57	mitogen-activated protein kinase 8	Homo sapiens	25-28
34504651-4	2021	Here, we showed the small molecule 5Z-7-oxozeaenol (5Z7O) induces dose-dependent cytotoxicity in a panel of T-ALL cell lines mainly through inhibition of the MAP2K7-JNK pathway, which further validates MAP2K7 as a therapeutic target.	5-7-oxo-zeaenol	35-50	mitogen-activated protein kinase kinase 7	Homo sapiens	158-164
34504651-4	2021	Here, we showed the small molecule 5Z-7-oxozeaenol (5Z7O) induces dose-dependent cytotoxicity in a panel of T-ALL cell lines mainly through inhibition of the MAP2K7-JNK pathway, which further validates MAP2K7 as a therapeutic target.	5-7-oxo-zeaenol	35-50	mitogen-activated protein kinase 8	Homo sapiens	165-168
34504651-4	2021	Here, we showed the small molecule 5Z-7-oxozeaenol (5Z7O) induces dose-dependent cytotoxicity in a panel of T-ALL cell lines mainly through inhibition of the MAP2K7-JNK pathway, which further validates MAP2K7 as a therapeutic target.	5-7-oxo-zeaenol	35-50	mitogen-activated protein kinase kinase 7	Homo sapiens	202-208
34504651-4	2021	Here, we showed the small molecule 5Z-7-oxozeaenol (5Z7O) induces dose-dependent cytotoxicity in a panel of T-ALL cell lines mainly through inhibition of the MAP2K7-JNK pathway, which further validates MAP2K7 as a therapeutic target.	5-7-oxo-zeaenol	52-56	mitogen-activated protein kinase kinase 7	Homo sapiens	158-164
34504651-4	2021	Here, we showed the small molecule 5Z-7-oxozeaenol (5Z7O) induces dose-dependent cytotoxicity in a panel of T-ALL cell lines mainly through inhibition of the MAP2K7-JNK pathway, which further validates MAP2K7 as a therapeutic target.	5-7-oxo-zeaenol	52-56	mitogen-activated protein kinase 8	Homo sapiens	165-168
34504651-4	2021	Here, we showed the small molecule 5Z-7-oxozeaenol (5Z7O) induces dose-dependent cytotoxicity in a panel of T-ALL cell lines mainly through inhibition of the MAP2K7-JNK pathway, which further validates MAP2K7 as a therapeutic target.	5-7-oxo-zeaenol	52-56	mitogen-activated protein kinase kinase 7	Homo sapiens	202-208
34504485-9	2021	Pharmacological blockade of the TGF-beta signalling pathway with SD208 (TGF-beta receptor type I inhibitor), SIS3 (Smad3 inhibitor) or (5Z)-7-oxozeaenol (TGF-beta-activated kinase 1 inhibitor) ameliorated fibronectin levels and type I collagen secretion.	5-7-oxo-zeaenol	135-152	transforming growth factor alpha	Homo sapiens	32-40
34504485-9	2021	Pharmacological blockade of the TGF-beta signalling pathway with SD208 (TGF-beta receptor type I inhibitor), SIS3 (Smad3 inhibitor) or (5Z)-7-oxozeaenol (TGF-beta-activated kinase 1 inhibitor) ameliorated fibronectin levels and type I collagen secretion.	5-7-oxo-zeaenol	135-152	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	154-181
34504485-9	2021	Pharmacological blockade of the TGF-beta signalling pathway with SD208 (TGF-beta receptor type I inhibitor), SIS3 (Smad3 inhibitor) or (5Z)-7-oxozeaenol (TGF-beta-activated kinase 1 inhibitor) ameliorated fibronectin levels and type I collagen secretion.	5-7-oxo-zeaenol	135-152	fibronectin 1	Homo sapiens	205-216
34358621-7	2021	In vitro analysis, after H9c2 cells were pretreated with or without PCr (0.5 mM) or NAC (0.5 mM) or 5Z-7-oxozeaenol (5z-7-Ox, 1 muM) for 1 h, subsequently treated with DOX (1 muM ) for 24 h. The results revealed that inhibition of TAK1 further deteriorated apoptotic and necroptotic cell death induced by DOX in H9c2 cells, but didn"t affect oxidative stress.	5-7-oxo-zeaenol	100-115	mitogen activated protein kinase kinase kinase 7	Rattus norvegicus	231-235
34358621-7	2021	In vitro analysis, after H9c2 cells were pretreated with or without PCr (0.5 mM) or NAC (0.5 mM) or 5Z-7-oxozeaenol (5z-7-Ox, 1 muM) for 1 h, subsequently treated with DOX (1 muM ) for 24 h. The results revealed that inhibition of TAK1 further deteriorated apoptotic and necroptotic cell death induced by DOX in H9c2 cells, but didn"t affect oxidative stress.	5-7-oxo-zeaenol	117-124	mitogen activated protein kinase kinase kinase 7	Rattus norvegicus	231-235
35489201-2	2022	Here we show that mascRNA, a tRNA-like cytoplasmic small noncoding RNA, promoted RIPK1-dependent apoptosis (RDA) in RAW267.4 macrophages in response to the TAK1 inhibitor 5Z-7-oxozeaenol (5Z-7) alone as well as in combination with TNF.	5-7-oxo-zeaenol	171-186	receptor (TNFRSF)-interacting serine-threonine kinase 1	Mus musculus	81-86
35489201-2	2022	Here we show that mascRNA, a tRNA-like cytoplasmic small noncoding RNA, promoted RIPK1-dependent apoptosis (RDA) in RAW267.4 macrophages in response to the TAK1 inhibitor 5Z-7-oxozeaenol (5Z-7) alone as well as in combination with TNF.	5-7-oxo-zeaenol	171-186	mitogen-activated protein kinase kinase kinase 7	Mus musculus	156-160
35489201-2	2022	Here we show that mascRNA, a tRNA-like cytoplasmic small noncoding RNA, promoted RIPK1-dependent apoptosis (RDA) in RAW267.4 macrophages in response to the TAK1 inhibitor 5Z-7-oxozeaenol (5Z-7) alone as well as in combination with TNF.	5-7-oxo-zeaenol	171-186	tumor necrosis factor	Mus musculus	231-234
35184673-2	2022	HK-2 cells were cultured in high glucose medium with and without TAK1 inhibitor 5Z-7-oxozeaenol.	5-7-oxo-zeaenol	80-95	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	65-69
34461942-6	2021	A selective TAK1 inhibitor, 5Z-7-oxozeaenol (OZ) was administered by intracerebroventricular (i.c.v) injection at 30 min after SAH induction.	5-7-oxo-zeaenol	28-43	mitogen-activated protein kinase kinase kinase 7	Mus musculus	12-16
35324316-4	2022	We observed that inhibition of TAK1 with 5Z-7-oxozeaenol (OZ) markedly reduced expression of beta-catenin and VE-cadherin at endothelial adherens junctions and augmented protease-activated receptor-1 (PAR-1)- or toll like receptor-4 (TLR-4)-induced increases in lung vascular permeability.	5-7-oxo-zeaenol	41-56	mitogen-activated protein kinase kinase kinase 7	Mus musculus	31-35
35324316-4	2022	We observed that inhibition of TAK1 with 5Z-7-oxozeaenol (OZ) markedly reduced expression of beta-catenin and VE-cadherin at endothelial adherens junctions and augmented protease-activated receptor-1 (PAR-1)- or toll like receptor-4 (TLR-4)-induced increases in lung vascular permeability.	5-7-oxo-zeaenol	41-56	catenin (cadherin associated protein), beta 1	Mus musculus	93-105
35324316-4	2022	We observed that inhibition of TAK1 with 5Z-7-oxozeaenol (OZ) markedly reduced expression of beta-catenin and VE-cadherin at endothelial adherens junctions and augmented protease-activated receptor-1 (PAR-1)- or toll like receptor-4 (TLR-4)-induced increases in lung vascular permeability.	5-7-oxo-zeaenol	41-56	cadherin 5	Mus musculus	110-121
35324316-4	2022	We observed that inhibition of TAK1 with 5Z-7-oxozeaenol (OZ) markedly reduced expression of beta-catenin and VE-cadherin at endothelial adherens junctions and augmented protease-activated receptor-1 (PAR-1)- or toll like receptor-4 (TLR-4)-induced increases in lung vascular permeability.	5-7-oxo-zeaenol	41-56	coagulation factor II (thrombin) receptor	Mus musculus	170-199
35324316-4	2022	We observed that inhibition of TAK1 with 5Z-7-oxozeaenol (OZ) markedly reduced expression of beta-catenin and VE-cadherin at endothelial adherens junctions and augmented protease-activated receptor-1 (PAR-1)- or toll like receptor-4 (TLR-4)-induced increases in lung vascular permeability.	5-7-oxo-zeaenol	41-56	coagulation factor II (thrombin) receptor	Mus musculus	201-206
35324316-4	2022	We observed that inhibition of TAK1 with 5Z-7-oxozeaenol (OZ) markedly reduced expression of beta-catenin and VE-cadherin at endothelial adherens junctions and augmented protease-activated receptor-1 (PAR-1)- or toll like receptor-4 (TLR-4)-induced increases in lung vascular permeability.	5-7-oxo-zeaenol	41-56	toll-like receptor 4	Mus musculus	212-232
35324316-4	2022	We observed that inhibition of TAK1 with 5Z-7-oxozeaenol (OZ) markedly reduced expression of beta-catenin and VE-cadherin at endothelial adherens junctions and augmented protease-activated receptor-1 (PAR-1)- or toll like receptor-4 (TLR-4)-induced increases in lung vascular permeability.	5-7-oxo-zeaenol	41-56	toll-like receptor 4	Mus musculus	234-239
35324316-4	2022	We observed that inhibition of TAK1 with 5Z-7-oxozeaenol (OZ) markedly reduced expression of beta-catenin and VE-cadherin at endothelial adherens junctions and augmented protease-activated receptor-1 (PAR-1)- or toll like receptor-4 (TLR-4)-induced increases in lung vascular permeability.	5-7-oxo-zeaenol	58-60	mitogen-activated protein kinase kinase kinase 7	Mus musculus	31-35
35324316-4	2022	We observed that inhibition of TAK1 with 5Z-7-oxozeaenol (OZ) markedly reduced expression of beta-catenin and VE-cadherin at endothelial adherens junctions and augmented protease-activated receptor-1 (PAR-1)- or toll like receptor-4 (TLR-4)-induced increases in lung vascular permeability.	5-7-oxo-zeaenol	58-60	catenin (cadherin associated protein), beta 1	Mus musculus	93-105
35324316-4	2022	We observed that inhibition of TAK1 with 5Z-7-oxozeaenol (OZ) markedly reduced expression of beta-catenin and VE-cadherin at endothelial adherens junctions and augmented protease-activated receptor-1 (PAR-1)- or toll like receptor-4 (TLR-4)-induced increases in lung vascular permeability.	5-7-oxo-zeaenol	58-60	cadherin 5	Mus musculus	110-121
35324316-4	2022	We observed that inhibition of TAK1 with 5Z-7-oxozeaenol (OZ) markedly reduced expression of beta-catenin and VE-cadherin at endothelial adherens junctions and augmented protease-activated receptor-1 (PAR-1)- or toll like receptor-4 (TLR-4)-induced increases in lung vascular permeability.	5-7-oxo-zeaenol	58-60	coagulation factor II (thrombin) receptor	Mus musculus	170-199
35324316-4	2022	We observed that inhibition of TAK1 with 5Z-7-oxozeaenol (OZ) markedly reduced expression of beta-catenin and VE-cadherin at endothelial adherens junctions and augmented protease-activated receptor-1 (PAR-1)- or toll like receptor-4 (TLR-4)-induced increases in lung vascular permeability.	5-7-oxo-zeaenol	58-60	coagulation factor II (thrombin) receptor	Mus musculus	201-206
35324316-4	2022	We observed that inhibition of TAK1 with 5Z-7-oxozeaenol (OZ) markedly reduced expression of beta-catenin and VE-cadherin at endothelial adherens junctions and augmented protease-activated receptor-1 (PAR-1)- or toll like receptor-4 (TLR-4)-induced increases in lung vascular permeability.	5-7-oxo-zeaenol	58-60	toll-like receptor 4	Mus musculus	212-232
35324316-4	2022	We observed that inhibition of TAK1 with 5Z-7-oxozeaenol (OZ) markedly reduced expression of beta-catenin and VE-cadherin at endothelial adherens junctions and augmented protease-activated receptor-1 (PAR-1)- or toll like receptor-4 (TLR-4)-induced increases in lung vascular permeability.	5-7-oxo-zeaenol	58-60	toll-like receptor 4	Mus musculus	234-239
34976206-4	2022	Methods: Angiogenic activities were assessed in ex vivo and in vitro models subjected to TAK1 inhibition by 5Z-7-oxozeaenol, a selective inhibitor of TAK1.	5-7-oxo-zeaenol	108-123	mitogen-activated protein kinase kinase kinase 7	Mus musculus	150-154
34976206-9	2022	In addition, inhibition of TAK1 by 5Z-7-oxozeaenol blocked TNFalpha-mediated NFkappaB signalling, and its downstream genes related to angiogenesis and inflammation.	5-7-oxo-zeaenol	35-50	mitogen-activated protein kinase kinase kinase 7	Mus musculus	27-31
33966040-6	2021	GANT61-induced autophagy was blocked by TAK1 siRNA and the inhibitors of TAK1 (5Z-7-oxozeaenol, 5Z), JNK (SP600125), and AMPK (Compound C, CC).	5-7-oxo-zeaenol	79-94	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	73-77
33542218-3	2021	In this study, we found that poly(I:C) + TAK1 inhibitor 5Z-7-oxozeaenol (P5) concurrently induces RDA and necroptosis in Abin-1-/-, but not in Abin-1+/+ mouse embryonic fibroblasts (MEFs).	5-7-oxo-zeaenol	56-71	mitogen-activated protein kinase kinase kinase 7	Mus musculus	41-45
33549727-7	2021	Compared with controls, mice that received 5Z-7-oxozeaenol showed decreased development of morphine tolerance and inhibition on repeated morphine-induced increase of NLRP3 but not TLR4.	5-7-oxo-zeaenol	43-58	NLR family, pyrin domain containing 3	Mus musculus	166-171
33549727-7	2021	Compared with controls, mice that received 5Z-7-oxozeaenol showed decreased development of morphine tolerance and inhibition on repeated morphine-induced increase of NLRP3 but not TLR4.	5-7-oxo-zeaenol	43-58	toll-like receptor 4	Mus musculus	180-184
33542218-3	2021	In this study, we found that poly(I:C) + TAK1 inhibitor 5Z-7-oxozeaenol (P5) concurrently induces RDA and necroptosis in Abin-1-/-, but not in Abin-1+/+ mouse embryonic fibroblasts (MEFs).	5-7-oxo-zeaenol	56-71	TNFAIP3 interacting protein 1	Mus musculus	121-127
33086897-3	2020	TAK1 inhibitors can induce the apoptosis of cancerous cells, and irreversible inhibitors such as (5Z)-7-oxozeaenol are highly potent.	5-7-oxo-zeaenol	97-114	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	0-4
33137362-6	2020	Pharmacological compounds with potent anti-BIKE activity, including the investigational anticancer drug 5Z-7-oxozeaenol and more selective inhibitors, suppress DENV infection both in vitro and ex vivo.	5-7-oxo-zeaenol	104-119	BMP2 inducible kinase	Homo sapiens	43-47
33375627-5	2020	In vitro model, using GBM cell lines, showed that 5Z-7-oxozeaenol augmented the cytotoxic effects of TMZ, blocking TMZ-induced NF-kappaB-activation, reducing DNA-damage and enhancing TMZ-induced apoptosis in GMB cell lines.	5-7-oxo-zeaenol	50-65	nuclear factor kappa B subunit 1	Homo sapiens	127-136
33148869-11	2020	However, 5Z-7-oxozeaenol, SB203580 and U0126 only reversed the stimulatory effect of TGF-beta1 on ALP.	5-7-oxo-zeaenol	9-24	transforming growth factor beta 1	Homo sapiens	85-94
33148869-11	2020	However, 5Z-7-oxozeaenol, SB203580 and U0126 only reversed the stimulatory effect of TGF-beta1 on ALP.	5-7-oxo-zeaenol	9-24	alkaline phosphatase, placental	Homo sapiens	98-101
33148869-13	2020	TGF-beta1-stimulated TIMP-1 and N-cadherin was inhibited by SB431542 and 5Z-7-oxozeaenol.	5-7-oxo-zeaenol	73-88	transforming growth factor beta 1	Homo sapiens	0-9
33148869-13	2020	TGF-beta1-stimulated TIMP-1 and N-cadherin was inhibited by SB431542 and 5Z-7-oxozeaenol.	5-7-oxo-zeaenol	73-88	TIMP metallopeptidase inhibitor 1	Homo sapiens	21-27
33148869-13	2020	TGF-beta1-stimulated TIMP-1 and N-cadherin was inhibited by SB431542 and 5Z-7-oxozeaenol.	5-7-oxo-zeaenol	73-88	cadherin 2	Homo sapiens	32-42
32664789-3	2020	Data from The Genomics of Drug Sensitivity in Cancer database showed that three drugs: (5Z)-7-oxozeaenol, dabrafenib and nutlin-3a (-), have shown more resistance in patients with TP53 mutation.	5-7-oxo-zeaenol	87-104	tumor protein p53	Homo sapiens	180-184
32378287-4	2020	Mice (TAK1 inhibiting by 5Z-7-oxozeaenol or silencing by AAV9 vector) were exposed to MI/R injury.	5-7-oxo-zeaenol	25-40	mitogen-activated protein kinase kinase kinase 7	Mus musculus	6-10
32382778-13	2020	In contrast, 5Z-7-Oxozeaenol-induced pharmacological inhibition of TAK1 completely diminished MAPK-signalling including the kinases JNK and p38 in all cells.	5-7-oxo-zeaenol	13-28	mitogen-activated protein kinase kinase kinase 7	Mus musculus	67-71
32382778-13	2020	In contrast, 5Z-7-Oxozeaenol-induced pharmacological inhibition of TAK1 completely diminished MAPK-signalling including the kinases JNK and p38 in all cells.	5-7-oxo-zeaenol	13-28	mitogen-activated protein kinase 8	Mus musculus	132-135
32382778-13	2020	In contrast, 5Z-7-Oxozeaenol-induced pharmacological inhibition of TAK1 completely diminished MAPK-signalling including the kinases JNK and p38 in all cells.	5-7-oxo-zeaenol	13-28	mitogen-activated protein kinase 14	Mus musculus	140-143
32349637-7	2020	Furthermore, the increased inflammation and apoptosis seen in injured CARD3-TG brains were reversed by intravenous administration of the TAK1 inhibitor 5Z-7-oxozeaenol.	5-7-oxo-zeaenol	152-167	receptor (TNFRSF)-interacting serine-threonine kinase 2	Mus musculus	70-75
32349637-7	2020	Furthermore, the increased inflammation and apoptosis seen in injured CARD3-TG brains were reversed by intravenous administration of the TAK1 inhibitor 5Z-7-oxozeaenol.	5-7-oxo-zeaenol	152-167	mitogen-activated protein kinase kinase kinase 7	Mus musculus	137-141
30554141-10	2019	Antagonising TAK1, with 5(Z)-7-oxozeaenol, in vitro and in vivo led to an increase in fibre diameter and a reduction in mRNA expression of atrogin-1 in both C2C12 cells and in the TA of animals who continued to grow.	5-7-oxo-zeaenol	24-41	mitogen-activated protein kinase kinase kinase 7	Mus musculus	13-17
32108376-3	2020	We detect novel activation of TAK1 at Ser412 in response to IgE-mediated activation under SCF-c-kit potentiation in a mast cell-driven response characteristic of allergic inflammation, which is potently blocked by TAK1 inhibitor 5Z-7-oxozeaenol (OZ).	5-7-oxo-zeaenol	229-244	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	30-34
32108376-3	2020	We detect novel activation of TAK1 at Ser412 in response to IgE-mediated activation under SCF-c-kit potentiation in a mast cell-driven response characteristic of allergic inflammation, which is potently blocked by TAK1 inhibitor 5Z-7-oxozeaenol (OZ).	5-7-oxo-zeaenol	229-244	KIT ligand	Homo sapiens	90-93
32108376-3	2020	We detect novel activation of TAK1 at Ser412 in response to IgE-mediated activation under SCF-c-kit potentiation in a mast cell-driven response characteristic of allergic inflammation, which is potently blocked by TAK1 inhibitor 5Z-7-oxozeaenol (OZ).	5-7-oxo-zeaenol	229-244	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	94-99
32108376-3	2020	We detect novel activation of TAK1 at Ser412 in response to IgE-mediated activation under SCF-c-kit potentiation in a mast cell-driven response characteristic of allergic inflammation, which is potently blocked by TAK1 inhibitor 5Z-7-oxozeaenol (OZ).	5-7-oxo-zeaenol	229-244	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	214-218
32108376-3	2020	We detect novel activation of TAK1 at Ser412 in response to IgE-mediated activation under SCF-c-kit potentiation in a mast cell-driven response characteristic of allergic inflammation, which is potently blocked by TAK1 inhibitor 5Z-7-oxozeaenol (OZ).	5-7-oxo-zeaenol	246-248	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	30-34
32108376-3	2020	We detect novel activation of TAK1 at Ser412 in response to IgE-mediated activation under SCF-c-kit potentiation in a mast cell-driven response characteristic of allergic inflammation, which is potently blocked by TAK1 inhibitor 5Z-7-oxozeaenol (OZ).	5-7-oxo-zeaenol	246-248	KIT ligand	Homo sapiens	90-93
32108376-3	2020	We detect novel activation of TAK1 at Ser412 in response to IgE-mediated activation under SCF-c-kit potentiation in a mast cell-driven response characteristic of allergic inflammation, which is potently blocked by TAK1 inhibitor 5Z-7-oxozeaenol (OZ).	5-7-oxo-zeaenol	246-248	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	94-99
32108376-3	2020	We detect novel activation of TAK1 at Ser412 in response to IgE-mediated activation under SCF-c-kit potentiation in a mast cell-driven response characteristic of allergic inflammation, which is potently blocked by TAK1 inhibitor 5Z-7-oxozeaenol (OZ).	5-7-oxo-zeaenol	246-248	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	214-218
32078472-5	2020	TAK1 was targeted by tamoxifen-induced Mi/MPhi-specific knockout or administration of a selective inhibitor 5Z-7-Oxozeaenol after MCAO.	5-7-oxo-zeaenol	108-123	mitogen-activated protein kinase kinase kinase 7	Mus musculus	0-4
31668971-10	2019	To determine if Map3k7 is necessary for endoderm differentiation, EBs were grown in the presence of the Map3k7 specific inhibitor 5Z-7-oxozeaenol.	5-7-oxo-zeaenol	130-145	mitogen-activated protein kinase kinase kinase 7	Mus musculus	104-110
31539775-5	2019	JNK activation by the NS1 protein or by H5N1 virus was blocked by 5Z-7-Oxozeaenol (5Z), a TAK1-specific inhibitor, and by TAK1 siRNA.	5-7-oxo-zeaenol	66-81	mitogen-activated protein kinase 8	Homo sapiens	0-3
31539775-5	2019	JNK activation by the NS1 protein or by H5N1 virus was blocked by 5Z-7-Oxozeaenol (5Z), a TAK1-specific inhibitor, and by TAK1 siRNA.	5-7-oxo-zeaenol	66-81	influenza virus NS1A binding protein	Homo sapiens	22-25
31539775-5	2019	JNK activation by the NS1 protein or by H5N1 virus was blocked by 5Z-7-Oxozeaenol (5Z), a TAK1-specific inhibitor, and by TAK1 siRNA.	5-7-oxo-zeaenol	66-81	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	90-94
31376257-11	2020	Among them, TAK1 inhibitor, (5Z) -7-Oxozeaenol, showed a significant difference (p<0.05).	5-7-oxo-zeaenol	28-46	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	12-16
31376257-12	2020	Also, the decreased phosphorylation levels of ERK1/2 and p65 were detected with PD98059 and (5Z) -7-Oxozeaenol addition, respectively.	5-7-oxo-zeaenol	92-110	mitogen-activated protein kinase 3	Homo sapiens	46-52
31376257-12	2020	Also, the decreased phosphorylation levels of ERK1/2 and p65 were detected with PD98059 and (5Z) -7-Oxozeaenol addition, respectively.	5-7-oxo-zeaenol	92-110	RELA proto-oncogene, NF-kB subunit	Homo sapiens	57-60
30850732-4	2019	Interestingly, the activity of transforming growth factor beta-activated kinase 1 (TAK1) appears to prevent RIPK1 from contributing to cell death induction, since TAK1 inhibition by (5Z)-7-Oxozeaenol, deletion of MAP3K7 or the expression of inactive TAK1 were sufficient to sensitize melanoma cells to RIPK1-dependent cell death in response to TNFalpha or TRAIL based combination treatments.	5-7-oxo-zeaenol	182-199	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	31-81
30850732-4	2019	Interestingly, the activity of transforming growth factor beta-activated kinase 1 (TAK1) appears to prevent RIPK1 from contributing to cell death induction, since TAK1 inhibition by (5Z)-7-Oxozeaenol, deletion of MAP3K7 or the expression of inactive TAK1 were sufficient to sensitize melanoma cells to RIPK1-dependent cell death in response to TNFalpha or TRAIL based combination treatments.	5-7-oxo-zeaenol	182-199	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	83-87
30850732-4	2019	Interestingly, the activity of transforming growth factor beta-activated kinase 1 (TAK1) appears to prevent RIPK1 from contributing to cell death induction, since TAK1 inhibition by (5Z)-7-Oxozeaenol, deletion of MAP3K7 or the expression of inactive TAK1 were sufficient to sensitize melanoma cells to RIPK1-dependent cell death in response to TNFalpha or TRAIL based combination treatments.	5-7-oxo-zeaenol	182-199	receptor interacting serine/threonine kinase 1	Homo sapiens	108-113
30850732-4	2019	Interestingly, the activity of transforming growth factor beta-activated kinase 1 (TAK1) appears to prevent RIPK1 from contributing to cell death induction, since TAK1 inhibition by (5Z)-7-Oxozeaenol, deletion of MAP3K7 or the expression of inactive TAK1 were sufficient to sensitize melanoma cells to RIPK1-dependent cell death in response to TNFalpha or TRAIL based combination treatments.	5-7-oxo-zeaenol	182-199	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	163-167
30850732-4	2019	Interestingly, the activity of transforming growth factor beta-activated kinase 1 (TAK1) appears to prevent RIPK1 from contributing to cell death induction, since TAK1 inhibition by (5Z)-7-Oxozeaenol, deletion of MAP3K7 or the expression of inactive TAK1 were sufficient to sensitize melanoma cells to RIPK1-dependent cell death in response to TNFalpha or TRAIL based combination treatments.	5-7-oxo-zeaenol	182-199	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	163-167
30850732-6	2019	In addition, TAK1 inhibitor (5Z)-7-Oxozeaenol suppressed intrinsic or treatment-induced pro-survival signaling as well as the secretion of cytokines and soluble factors associated with melanoma disease progression.	5-7-oxo-zeaenol	29-45	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	13-17
31308811-7	2019	Rb1-induced Akt phosphorylation was inhibited by SB203580, (5Z)-7-oxozeaenol, and small-interfering RNA (siRNA)-mediated knockdown of p38alpha MAPK in macrophages.	5-7-oxo-zeaenol	59-76	RB transcriptional corepressor 1	Mus musculus	0-3
31308811-7	2019	Rb1-induced Akt phosphorylation was inhibited by SB203580, (5Z)-7-oxozeaenol, and small-interfering RNA (siRNA)-mediated knockdown of p38alpha MAPK in macrophages.	5-7-oxo-zeaenol	59-76	thymoma viral proto-oncogene 1	Mus musculus	12-15
30816448-7	2019	The anti-TLR4 antibody and TAK1 inhibitor 5Z-7-oxozeaenol partially attenuated the LPS-induced expression of proinflammatory cytokines.	5-7-oxo-zeaenol	42-57	mitogen activated protein kinase kinase kinase 7	Rattus norvegicus	27-31
30470856-8	2019	Pretreatment with 5Z-7-oxozeaenol (5 micromol/l), an inhibitor of TGF-beta-activated kinase 1, which is a key activator of alpha-tubulin acetyltransferase 1, did not affect the distribution and acetylation of microtubules in resting cells; however, it significantly suppressed antigen-evoked microtubule acetylation and their reorganization, and subsequent degranulation (95.0 +- 1.2% inhibition, n = 3, P &lt; 0.01).	5-7-oxo-zeaenol	18-33	mitogen activated protein kinase kinase kinase 7	Rattus norvegicus	66-93
30470856-8	2019	Pretreatment with 5Z-7-oxozeaenol (5 micromol/l), an inhibitor of TGF-beta-activated kinase 1, which is a key activator of alpha-tubulin acetyltransferase 1, did not affect the distribution and acetylation of microtubules in resting cells; however, it significantly suppressed antigen-evoked microtubule acetylation and their reorganization, and subsequent degranulation (95.0 +- 1.2% inhibition, n = 3, P &lt; 0.01).	5-7-oxo-zeaenol	18-33	alpha tubulin acetyltransferase 1	Rattus norvegicus	123-156
30554141-10	2019	Antagonising TAK1, with 5(Z)-7-oxozeaenol, in vitro and in vivo led to an increase in fibre diameter and a reduction in mRNA expression of atrogin-1 in both C2C12 cells and in the TA of animals who continued to grow.	5-7-oxo-zeaenol	24-41	F-box protein 32	Mus musculus	139-148
29777109-3	2018	Here, we show that nanoparticle-mediated delivery of transforming growth factor-beta1-activated kinase-1 (TAK1) inhibitor 5Z-7-Oxozeaenol can inhibit TNBC lung metastasis in most animals tested.	5-7-oxo-zeaenol	122-137	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	53-104
30381458-3	2018	Here, using Yersinia pseudotuberculosis in corroboration with costimulation of lipopolysaccharide and (5Z)-7-Oxozeaenol, a small-molecule inhibitor of TAK1, we show that caspase-8 activation during TAK1 inhibition results in cleavage of both gasdermin D (GSDMD) and gasdermin E (GSDME) in murine macrophages, resulting in pyroptosis.	5-7-oxo-zeaenol	102-119	caspase 8	Homo sapiens	170-179
29709340-12	2018	Pretreatment and co-incubation of pulp cells by 5z-7oxozeaenol (1 and 2.5 muM) and U0126 (10 and 20 muM) prevented the IL-1beta-induced IL-8 and uPA expression.	5-7-oxo-zeaenol	48-62	latexin	Homo sapiens	74-77
29709340-12	2018	Pretreatment and co-incubation of pulp cells by 5z-7oxozeaenol (1 and 2.5 muM) and U0126 (10 and 20 muM) prevented the IL-1beta-induced IL-8 and uPA expression.	5-7-oxo-zeaenol	48-62	latexin	Homo sapiens	100-103
29709340-12	2018	Pretreatment and co-incubation of pulp cells by 5z-7oxozeaenol (1 and 2.5 muM) and U0126 (10 and 20 muM) prevented the IL-1beta-induced IL-8 and uPA expression.	5-7-oxo-zeaenol	48-62	interleukin 1 beta	Homo sapiens	119-127
29709340-12	2018	Pretreatment and co-incubation of pulp cells by 5z-7oxozeaenol (1 and 2.5 muM) and U0126 (10 and 20 muM) prevented the IL-1beta-induced IL-8 and uPA expression.	5-7-oxo-zeaenol	48-62	C-X-C motif chemokine ligand 8	Homo sapiens	136-140
29709340-12	2018	Pretreatment and co-incubation of pulp cells by 5z-7oxozeaenol (1 and 2.5 muM) and U0126 (10 and 20 muM) prevented the IL-1beta-induced IL-8 and uPA expression.	5-7-oxo-zeaenol	48-62	plasminogen activator, urokinase	Homo sapiens	145-148
29709340-13	2018	5z-7oxozeaenol and U0126 also attenuated the IL-1beta-induced IL-8 and uPA secretion.	5-7-oxo-zeaenol	0-14	interleukin 1 beta	Homo sapiens	45-53
29709340-13	2018	5z-7oxozeaenol and U0126 also attenuated the IL-1beta-induced IL-8 and uPA secretion.	5-7-oxo-zeaenol	0-14	C-X-C motif chemokine ligand 8	Homo sapiens	62-66
29709340-13	2018	5z-7oxozeaenol and U0126 also attenuated the IL-1beta-induced IL-8 and uPA secretion.	5-7-oxo-zeaenol	0-14	plasminogen activator, urokinase	Homo sapiens	71-74
29777109-3	2018	Here, we show that nanoparticle-mediated delivery of transforming growth factor-beta1-activated kinase-1 (TAK1) inhibitor 5Z-7-Oxozeaenol can inhibit TNBC lung metastasis in most animals tested.	5-7-oxo-zeaenol	122-137	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	106-110
29373048-1	2018	OBJECTIVE: To investigate the effect of TGF-beta activated kinase-1(TAK1) inhibitor 5Z-7-oxozeaenol on the interaction between macrophages and mesangial cells exposed to high glucose.	5-7-oxo-zeaenol	84-99	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	40-72
29629569-3	2018	A 5-7-Oxozeaenol is selective inhibitor which irreversibly binds ERK2 by the formation of covalent bond with Cys166 while 5-iodotubercidin binds noncovalently.	5-7-oxo-zeaenol	2-16	mitogen-activated protein kinase 1	Homo sapiens	65-69
27723266-12	2018	In addition, SB431542, 5z-7-oxozeaenol and U0126 attenuated the TGF-beta1-induced secretion of PAI-1 and suPAR.	5-7-oxo-zeaenol	23-38	transforming growth factor beta 1	Homo sapiens	64-73
27723266-12	2018	In addition, SB431542, 5z-7-oxozeaenol and U0126 attenuated the TGF-beta1-induced secretion of PAI-1 and suPAR.	5-7-oxo-zeaenol	23-38	serpin family E member 1	Homo sapiens	95-100
29163172-3	2017	However, the role and mechanism of the TAK1 inhibitor 5Z-7-oxozeaenol in treating autoimmune demyelinating diseases remain unclear.	5-7-oxo-zeaenol	54-69	mitogen-activated protein kinase kinase kinase 7	Mus musculus	39-43
29027124-6	2018	5Z-7-oxozeaenol, a selective inhibitor of TAK1, reduced proinflammatory cytokine production by activated monocytes under lipopolysaccharide stimulation and T cell proliferation in allogeneic-mixed leukocyte reactions with monocyte-derived dendritic cells.	5-7-oxo-zeaenol	0-15	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	42-46
29027124-7	2018	In an experimental mouse model of GVHD, 5Z-7-oxozeaenol administration after allo-HCT ameliorated GVHD severity and mortality, with significant reduction in serum TNFalpha, IL-1beta, and IL-12 levels.	5-7-oxo-zeaenol	40-55	tumor necrosis factor	Mus musculus	163-171
29027124-7	2018	In an experimental mouse model of GVHD, 5Z-7-oxozeaenol administration after allo-HCT ameliorated GVHD severity and mortality, with significant reduction in serum TNFalpha, IL-1beta, and IL-12 levels.	5-7-oxo-zeaenol	40-55	interleukin 1 beta	Mus musculus	173-181
29163172-5	2017	Here, we demonstrate that 5Z-7-oxozeaenol efficiently alleviates the symptoms of EAE by decreasing the levels of pro-inflammatory cytokines in splenocytes and central nervous system, diminishing the number of activated microglia and inhibiting the p38MAPK, JNK, and ERK signaling pathways.	5-7-oxo-zeaenol	26-41	mitogen-activated protein kinase 14	Mus musculus	248-255
29163172-5	2017	Here, we demonstrate that 5Z-7-oxozeaenol efficiently alleviates the symptoms of EAE by decreasing the levels of pro-inflammatory cytokines in splenocytes and central nervous system, diminishing the number of activated microglia and inhibiting the p38MAPK, JNK, and ERK signaling pathways.	5-7-oxo-zeaenol	26-41	mitogen-activated protein kinase 8	Mus musculus	257-260
29163172-5	2017	Here, we demonstrate that 5Z-7-oxozeaenol efficiently alleviates the symptoms of EAE by decreasing the levels of pro-inflammatory cytokines in splenocytes and central nervous system, diminishing the number of activated microglia and inhibiting the p38MAPK, JNK, and ERK signaling pathways.	5-7-oxo-zeaenol	26-41	mitogen-activated protein kinase 1	Mus musculus	266-269
28668088-10	2017	Treatment with the TAK1 inihibitor (5Z)-7-oxozeaenol reduced ADAMTS-4 and MMP3 mRNA (0.5-fold and 0.6-fold, respectively) and protein expression (1.4-fold and 0.5-fold, respectively) in OA synovial cells.	5-7-oxo-zeaenol	36-52	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	19-23
28224764-6	2017	Furthermore, we determined the effect of 5Z-7-oxozeaenol (5Z-O), a TAK1-specific small molecule inhibitor, on proliferation of human TNBC cell line.	5-7-oxo-zeaenol	41-56	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	67-71
28224764-6	2017	Furthermore, we determined the effect of 5Z-7-oxozeaenol (5Z-O), a TAK1-specific small molecule inhibitor, on proliferation of human TNBC cell line.	5-7-oxo-zeaenol	58-62	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	67-71
28714004-4	2017	In addition, the effect of the TAK1 selective inhibitor 5Z-7-oxozeaenol (OZ) on the biological characteristics of MGC803 human gastric cancer cells in vitro were investigated.	5-7-oxo-zeaenol	56-71	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	31-35
28714004-9	2017	In addition, treatment with the TAK1 selective inhibitor OZ reduced the proliferation and invasion abilities of MGC803 cells and significantly reduced the expression levels of phosphorylated-TAK1 (Thr187), nuclear p65, cyclin D1, Bcl-2 apoptosis regulator and matrix metallopeptidase (MMP)9 (P&lt;0.05).	5-7-oxo-zeaenol	57-59	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	32-36
28714004-9	2017	In addition, treatment with the TAK1 selective inhibitor OZ reduced the proliferation and invasion abilities of MGC803 cells and significantly reduced the expression levels of phosphorylated-TAK1 (Thr187), nuclear p65, cyclin D1, Bcl-2 apoptosis regulator and matrix metallopeptidase (MMP)9 (P&lt;0.05).	5-7-oxo-zeaenol	57-59	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	191-195
28714004-9	2017	In addition, treatment with the TAK1 selective inhibitor OZ reduced the proliferation and invasion abilities of MGC803 cells and significantly reduced the expression levels of phosphorylated-TAK1 (Thr187), nuclear p65, cyclin D1, Bcl-2 apoptosis regulator and matrix metallopeptidase (MMP)9 (P&lt;0.05).	5-7-oxo-zeaenol	57-59	RELA proto-oncogene, NF-kB subunit	Homo sapiens	214-217
28714004-9	2017	In addition, treatment with the TAK1 selective inhibitor OZ reduced the proliferation and invasion abilities of MGC803 cells and significantly reduced the expression levels of phosphorylated-TAK1 (Thr187), nuclear p65, cyclin D1, Bcl-2 apoptosis regulator and matrix metallopeptidase (MMP)9 (P&lt;0.05).	5-7-oxo-zeaenol	57-59	cyclin D1	Homo sapiens	219-228
28714004-9	2017	In addition, treatment with the TAK1 selective inhibitor OZ reduced the proliferation and invasion abilities of MGC803 cells and significantly reduced the expression levels of phosphorylated-TAK1 (Thr187), nuclear p65, cyclin D1, Bcl-2 apoptosis regulator and matrix metallopeptidase (MMP)9 (P&lt;0.05).	5-7-oxo-zeaenol	57-59	matrix metallopeptidase 9	Homo sapiens	285-290
28668088-10	2017	Treatment with the TAK1 inihibitor (5Z)-7-oxozeaenol reduced ADAMTS-4 and MMP3 mRNA (0.5-fold and 0.6-fold, respectively) and protein expression (1.4-fold and 0.5-fold, respectively) in OA synovial cells.	5-7-oxo-zeaenol	36-52	ADAM metallopeptidase with thrombospondin type 1 motif 4	Homo sapiens	61-69
28668088-10	2017	Treatment with the TAK1 inihibitor (5Z)-7-oxozeaenol reduced ADAMTS-4 and MMP3 mRNA (0.5-fold and 0.6-fold, respectively) and protein expression (1.4-fold and 0.5-fold, respectively) in OA synovial cells.	5-7-oxo-zeaenol	36-52	matrix metallopeptidase 3	Homo sapiens	74-78
28668088-12	2017	(5Z)-7-oxozeaenol treatment reduced mPGES1 and NGF mRNA (1.5-fold and 0.8-fold, respectively) and protein (1.5-fold and 0.5-fold, respectively).	5-7-oxo-zeaenol	0-17	prostaglandin E synthase	Mus musculus	36-42
28668088-12	2017	(5Z)-7-oxozeaenol treatment reduced mPGES1 and NGF mRNA (1.5-fold and 0.8-fold, respectively) and protein (1.5-fold and 0.5-fold, respectively).	5-7-oxo-zeaenol	0-17	nerve growth factor	Homo sapiens	47-50
28474507-11	2017	Both 5Z-7-oxozeaenol and BAY 11-7082 significantly inhibited IL-17F-induced IL-6 production in a dose-dependent manner.	5-7-oxo-zeaenol	5-20	interleukin 17F	Homo sapiens	61-67
28111999-0	2017	Enhancement of hyperthermia-induced apoptosis by 5Z-7-oxozeaenol, a TAK1 inhibitor, in Molt-4 cells.	5-7-oxo-zeaenol	49-64	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	68-72
28111999-2	2017	TAK1 inhibitor, 5Z-7-oxozeaenol (OZ) has been studied for its apoptotic effects.	5-7-oxo-zeaenol	16-31	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	0-4
28111999-2	2017	TAK1 inhibitor, 5Z-7-oxozeaenol (OZ) has been studied for its apoptotic effects.	5-7-oxo-zeaenol	33-35	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	0-4
28111999-8	2017	Furthermore, OZ pre-treatment promotes caspase-8 cleavage, Fas externalisation, caspase 3 activity and intracellular calcium ion levels.	5-7-oxo-zeaenol	13-15	caspase 8	Homo sapiens	39-48
28111999-8	2017	Furthermore, OZ pre-treatment promotes caspase-8 cleavage, Fas externalisation, caspase 3 activity and intracellular calcium ion levels.	5-7-oxo-zeaenol	13-15	caspase 3	Homo sapiens	80-89
28474507-11	2017	Both 5Z-7-oxozeaenol and BAY 11-7082 significantly inhibited IL-17F-induced IL-6 production in a dose-dependent manner.	5-7-oxo-zeaenol	5-20	interleukin 6	Homo sapiens	76-80
28430599-0	2017	TAK1 inhibitor 5Z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis.	5-7-oxo-zeaenol	15-30	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	0-4
28569204-16	2017	Furthermore, our data regarding (5Z)-7-Oxozeaenol suggest that TAK1 facilitates Smad-dependent signaling.	5-7-oxo-zeaenol	32-49	SMAD family member 1	Bos taurus	80-84
28430599-4	2017	We found that TAK1 inhibitor 5Z-7-oxozeaenol significantly augmented the cytotoxic effects of Dox in a panel of cervical cancer cell lines.	5-7-oxo-zeaenol	29-44	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	14-18
27448221-0	2016	Enhancement of hyperthermia-induced apoptosis by 5Z-7-oxozeaenol, a TAK1 inhibitor, in A549 cells.	5-7-oxo-zeaenol	49-64	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	68-72
27764753-5	2016	Inactivation of TAK1 by inhibitor 5Z-7-oxozeaenol or gene knockdown sensitized taxol cytotoxicity in vitro, promoting cell apoptosis and mitosis arrest.	5-7-oxo-zeaenol	34-49	mitogen-activated protein kinase kinase kinase 7	Mus musculus	16-20
28389629-6	2017	5Z-7-oxozeaenol, a specific inhibitor of TAK1, or TAK1 siRNA blocked A77 1726-induced activation of AMPK and JNK, and LC3 lipidation.	5-7-oxo-zeaenol	0-15	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	41-45
28389629-6	2017	5Z-7-oxozeaenol, a specific inhibitor of TAK1, or TAK1 siRNA blocked A77 1726-induced activation of AMPK and JNK, and LC3 lipidation.	5-7-oxo-zeaenol	0-15	mitogen-activated protein kinase 8	Homo sapiens	109-112
28389629-6	2017	5Z-7-oxozeaenol, a specific inhibitor of TAK1, or TAK1 siRNA blocked A77 1726-induced activation of AMPK and JNK, and LC3 lipidation.	5-7-oxo-zeaenol	0-15	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	118-121
28039587-7	2017	5Z-7-oxozeaenol [(a TGF-beta-activated kinase 1 (TAK-1) inhibitor)] also attenuated the TGF-beta-mediated inhibition of apoM expression and suppressed the activation of JNK and c-Jun.	5-7-oxo-zeaenol	0-15	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	20-47
28039587-7	2017	5Z-7-oxozeaenol [(a TGF-beta-activated kinase 1 (TAK-1) inhibitor)] also attenuated the TGF-beta-mediated inhibition of apoM expression and suppressed the activation of JNK and c-Jun.	5-7-oxo-zeaenol	0-15	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	49-54
28039587-7	2017	5Z-7-oxozeaenol [(a TGF-beta-activated kinase 1 (TAK-1) inhibitor)] also attenuated the TGF-beta-mediated inhibition of apoM expression and suppressed the activation of JNK and c-Jun.	5-7-oxo-zeaenol	0-15	transforming growth factor beta 1	Homo sapiens	20-28
28039587-7	2017	5Z-7-oxozeaenol [(a TGF-beta-activated kinase 1 (TAK-1) inhibitor)] also attenuated the TGF-beta-mediated inhibition of apoM expression and suppressed the activation of JNK and c-Jun.	5-7-oxo-zeaenol	0-15	apolipoprotein M	Homo sapiens	120-124
28039587-7	2017	5Z-7-oxozeaenol [(a TGF-beta-activated kinase 1 (TAK-1) inhibitor)] also attenuated the TGF-beta-mediated inhibition of apoM expression and suppressed the activation of JNK and c-Jun.	5-7-oxo-zeaenol	0-15	mitogen-activated protein kinase 8	Homo sapiens	169-172
28039587-7	2017	5Z-7-oxozeaenol [(a TGF-beta-activated kinase 1 (TAK-1) inhibitor)] also attenuated the TGF-beta-mediated inhibition of apoM expression and suppressed the activation of JNK and c-Jun.	5-7-oxo-zeaenol	0-15	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	177-182
27876620-9	2017	CGP7930 enhanced the phosphorylation of transforming growth factor-beta-activated kinase 1 (TAK-1) and TAK-1 inhibition by 5Z-7-oxozeaenol reduced CGP7930-induced ERK1/2 phosphorylation.	5-7-oxo-zeaenol	123-138	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	40-90
27876620-9	2017	CGP7930 enhanced the phosphorylation of transforming growth factor-beta-activated kinase 1 (TAK-1) and TAK-1 inhibition by 5Z-7-oxozeaenol reduced CGP7930-induced ERK1/2 phosphorylation.	5-7-oxo-zeaenol	123-138	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	103-108
27876620-9	2017	CGP7930 enhanced the phosphorylation of transforming growth factor-beta-activated kinase 1 (TAK-1) and TAK-1 inhibition by 5Z-7-oxozeaenol reduced CGP7930-induced ERK1/2 phosphorylation.	5-7-oxo-zeaenol	123-138	mitogen-activated protein kinase 3	Homo sapiens	163-169
27820799-4	2017	(5z)-7-oxozeaenol (5ZO), a preclinical drug that targets transforming growth factor-beta-activated kinase 1 (TAK1), was more effective at blocking SF activation across all contexts than the approved drug tofacitinib, which supports the development of molecules similar to 5ZO for use as RA therapeutics.	5-7-oxo-zeaenol	0-17	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	57-107
27820799-4	2017	(5z)-7-oxozeaenol (5ZO), a preclinical drug that targets transforming growth factor-beta-activated kinase 1 (TAK1), was more effective at blocking SF activation across all contexts than the approved drug tofacitinib, which supports the development of molecules similar to 5ZO for use as RA therapeutics.	5-7-oxo-zeaenol	0-17	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	109-113
27820799-4	2017	(5z)-7-oxozeaenol (5ZO), a preclinical drug that targets transforming growth factor-beta-activated kinase 1 (TAK1), was more effective at blocking SF activation across all contexts than the approved drug tofacitinib, which supports the development of molecules similar to 5ZO for use as RA therapeutics.	5-7-oxo-zeaenol	19-22	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	57-107
27820799-4	2017	(5z)-7-oxozeaenol (5ZO), a preclinical drug that targets transforming growth factor-beta-activated kinase 1 (TAK1), was more effective at blocking SF activation across all contexts than the approved drug tofacitinib, which supports the development of molecules similar to 5ZO for use as RA therapeutics.	5-7-oxo-zeaenol	19-22	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	109-113
27572150-7	2016	Blocking transforming growth factor-beta-activated kinase 1-p38/c-Jun N-terminal kinase 1/2 signaling with a pharmacological inhibitor (5Z-7-oxozeaenol) greatly reversed the detrimental effects observed in USP18-knockout mice subjected to aortic banding.	5-7-oxo-zeaenol	136-151	mitogen-activated protein kinase 14	Mus musculus	60-63
27572150-7	2016	Blocking transforming growth factor-beta-activated kinase 1-p38/c-Jun N-terminal kinase 1/2 signaling with a pharmacological inhibitor (5Z-7-oxozeaenol) greatly reversed the detrimental effects observed in USP18-knockout mice subjected to aortic banding.	5-7-oxo-zeaenol	136-151	mitogen-activated protein kinase 8	Mus musculus	64-89
27572150-7	2016	Blocking transforming growth factor-beta-activated kinase 1-p38/c-Jun N-terminal kinase 1/2 signaling with a pharmacological inhibitor (5Z-7-oxozeaenol) greatly reversed the detrimental effects observed in USP18-knockout mice subjected to aortic banding.	5-7-oxo-zeaenol	136-151	ubiquitin specific peptidase 18	Mus musculus	206-211
27448221-4	2016	Annexin V-FITC/PI assay, cell cycle analysis, and colony formation assay revealed a significant enhancement in apoptosis induced by HT treatment, when the cells were pre-incubated with 5Z-7-oxozeaenol in a dose-dependent manner.	5-7-oxo-zeaenol	185-200	annexin A5	Homo sapiens	0-9
27448221-6	2016	In addition, western blot showed that 5Z-7-oxozeaenol enhanced HT-induced expressions of cleaved caspase-3, cleaved caspase-8, and HSP70 and decreased HT-induced expressions of Bcl-2, p-p38, p-JNK, and LC3.	5-7-oxo-zeaenol	38-53	caspase 8	Homo sapiens	116-125
27448221-6	2016	In addition, western blot showed that 5Z-7-oxozeaenol enhanced HT-induced expressions of cleaved caspase-3, cleaved caspase-8, and HSP70 and decreased HT-induced expressions of Bcl-2, p-p38, p-JNK, and LC3.	5-7-oxo-zeaenol	38-53	heat shock protein family A (Hsp70) member 4	Homo sapiens	131-136
27448221-6	2016	In addition, western blot showed that 5Z-7-oxozeaenol enhanced HT-induced expressions of cleaved caspase-3, cleaved caspase-8, and HSP70 and decreased HT-induced expressions of Bcl-2, p-p38, p-JNK, and LC3.	5-7-oxo-zeaenol	38-53	BCL2 apoptosis regulator	Homo sapiens	177-182
27448221-6	2016	In addition, western blot showed that 5Z-7-oxozeaenol enhanced HT-induced expressions of cleaved caspase-3, cleaved caspase-8, and HSP70 and decreased HT-induced expressions of Bcl-2, p-p38, p-JNK, and LC3.	5-7-oxo-zeaenol	38-53	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	202-205
27448221-8	2016	Taken together, our data provides further insights of the mechanism of action of 5Z-7-oxozeaenol and HT treatment, and their potential application as a novel approache to treat patients with KRAS mutant lung cancer.	5-7-oxo-zeaenol	81-96	KRAS proto-oncogene, GTPase	Homo sapiens	191-195
27448221-3	2016	In this study, in order to find a useful approach to treat KRAS mutant lung cancer, we focused on the combined effects of 5Z-7-oxozeaenol, a TAK1 inhibitor, with hyperthermia (HT) in KRAS mutant lung cancer cell line A549.	5-7-oxo-zeaenol	122-137	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	141-145
27448221-3	2016	In this study, in order to find a useful approach to treat KRAS mutant lung cancer, we focused on the combined effects of 5Z-7-oxozeaenol, a TAK1 inhibitor, with hyperthermia (HT) in KRAS mutant lung cancer cell line A549.	5-7-oxo-zeaenol	122-137	KRAS proto-oncogene, GTPase	Homo sapiens	183-187
27268284-4	2016	In consistent, 5Z-7-oxozeaenol markedly reduced diabetes-induced albuminuria, histological changes, macrophage infiltration, and renal inflammatory cytokines expression and exerted its function through down-regulating ERK1/2, p38MAPK, NF-kappaB activation in the kidneys of db/db mice.	5-7-oxo-zeaenol	15-30	mitogen-activated protein kinase 3	Mus musculus	218-224
27268284-2	2016	We used bone marrow-derived macrophages (BMMs) and db/db mice to investigate the potential protective effects and mechanisms of TAK1 inhibitor (5Z-7-oxozeaenol) on diabetic kidney disease.	5-7-oxo-zeaenol	144-159	mitogen-activated protein kinase kinase kinase 7	Mus musculus	128-132
27268284-3	2016	The study showed that pretreatment with 5Z-7-oxozeaenol not only remarkably decreased high glucose (HG) stimulated excessive release of MCP-1 and TNF-alpha, but also significantly down-regulated ERK1/2, p38MAPK phosphorylation, and NF-kappaB activation in macrophages.	5-7-oxo-zeaenol	40-55	mast cell protease 1	Mus musculus	136-141
27268284-4	2016	In consistent, 5Z-7-oxozeaenol markedly reduced diabetes-induced albuminuria, histological changes, macrophage infiltration, and renal inflammatory cytokines expression and exerted its function through down-regulating ERK1/2, p38MAPK, NF-kappaB activation in the kidneys of db/db mice.	5-7-oxo-zeaenol	15-30	mitogen-activated protein kinase 14	Mus musculus	226-233
26492523-11	2016	Aspirin, U0126, LY294002 and 5z-7-oxozeaenol attenuated the IL-1beta-induced MCP-1 expression.	5-7-oxo-zeaenol	29-44	interleukin 1 beta	Homo sapiens	60-68
27268284-3	2016	The study showed that pretreatment with 5Z-7-oxozeaenol not only remarkably decreased high glucose (HG) stimulated excessive release of MCP-1 and TNF-alpha, but also significantly down-regulated ERK1/2, p38MAPK phosphorylation, and NF-kappaB activation in macrophages.	5-7-oxo-zeaenol	40-55	tumor necrosis factor	Mus musculus	146-155
27268284-3	2016	The study showed that pretreatment with 5Z-7-oxozeaenol not only remarkably decreased high glucose (HG) stimulated excessive release of MCP-1 and TNF-alpha, but also significantly down-regulated ERK1/2, p38MAPK phosphorylation, and NF-kappaB activation in macrophages.	5-7-oxo-zeaenol	40-55	mitogen-activated protein kinase 3	Mus musculus	195-201
27268284-3	2016	The study showed that pretreatment with 5Z-7-oxozeaenol not only remarkably decreased high glucose (HG) stimulated excessive release of MCP-1 and TNF-alpha, but also significantly down-regulated ERK1/2, p38MAPK phosphorylation, and NF-kappaB activation in macrophages.	5-7-oxo-zeaenol	40-55	mitogen-activated protein kinase 14	Mus musculus	203-210
27012613-8	2016	After 5z-7-oxozeaenol treatment in epileptic rats, TRAF6-TAK1-P-TAK1 signaling protein expressions were reduced, inflammatory cytokine IL-1beta expression was decreased, neuron survival index was improved, the neuron apoptosis index was decreased and seizure durations were alleviated.	5-7-oxo-zeaenol	6-21	TNF receptor associated factor 6	Rattus norvegicus	51-56
27012613-8	2016	After 5z-7-oxozeaenol treatment in epileptic rats, TRAF6-TAK1-P-TAK1 signaling protein expressions were reduced, inflammatory cytokine IL-1beta expression was decreased, neuron survival index was improved, the neuron apoptosis index was decreased and seizure durations were alleviated.	5-7-oxo-zeaenol	6-21	mitogen activated protein kinase kinase kinase 7	Rattus norvegicus	57-61
27012613-8	2016	After 5z-7-oxozeaenol treatment in epileptic rats, TRAF6-TAK1-P-TAK1 signaling protein expressions were reduced, inflammatory cytokine IL-1beta expression was decreased, neuron survival index was improved, the neuron apoptosis index was decreased and seizure durations were alleviated.	5-7-oxo-zeaenol	6-21	mitogen activated protein kinase kinase kinase 7	Rattus norvegicus	64-68
27012613-8	2016	After 5z-7-oxozeaenol treatment in epileptic rats, TRAF6-TAK1-P-TAK1 signaling protein expressions were reduced, inflammatory cytokine IL-1beta expression was decreased, neuron survival index was improved, the neuron apoptosis index was decreased and seizure durations were alleviated.	5-7-oxo-zeaenol	6-21	interleukin 1 beta	Rattus norvegicus	135-143
26931406-5	2016	The anisomycin-induced increase in Forster resonance energy transfer was abolished by the TAK1 inhibitor (5z)-7-oxozeaenol.	5-7-oxo-zeaenol	105-122	mitogen-activated protein kinase kinase kinase 7	Mus musculus	90-94
26687627-7	2016	The results also suggested that TAK1 inhibitor (5Z-7-oxozeaenol) could inhibit AGEs-induced macrophage activation to down-regulate inflammatory cytokine production via MAPKs and NF-kappaB pathways, indicating that 5Z-7-oxozeaenol might be an immunoregulatory agent against AGEs-stimulated inflammatory response in DN.	5-7-oxo-zeaenol	48-63	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	32-36
26687627-7	2016	The results also suggested that TAK1 inhibitor (5Z-7-oxozeaenol) could inhibit AGEs-induced macrophage activation to down-regulate inflammatory cytokine production via MAPKs and NF-kappaB pathways, indicating that 5Z-7-oxozeaenol might be an immunoregulatory agent against AGEs-stimulated inflammatory response in DN.	5-7-oxo-zeaenol	48-63	nuclear factor kappa B subunit 1	Homo sapiens	178-187
26687627-7	2016	The results also suggested that TAK1 inhibitor (5Z-7-oxozeaenol) could inhibit AGEs-induced macrophage activation to down-regulate inflammatory cytokine production via MAPKs and NF-kappaB pathways, indicating that 5Z-7-oxozeaenol might be an immunoregulatory agent against AGEs-stimulated inflammatory response in DN.	5-7-oxo-zeaenol	214-229	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	32-36
26687627-7	2016	The results also suggested that TAK1 inhibitor (5Z-7-oxozeaenol) could inhibit AGEs-induced macrophage activation to down-regulate inflammatory cytokine production via MAPKs and NF-kappaB pathways, indicating that 5Z-7-oxozeaenol might be an immunoregulatory agent against AGEs-stimulated inflammatory response in DN.	5-7-oxo-zeaenol	214-229	nuclear factor kappa B subunit 1	Homo sapiens	178-187
26492523-11	2016	Aspirin, U0126, LY294002 and 5z-7-oxozeaenol attenuated the IL-1beta-induced MCP-1 expression.	5-7-oxo-zeaenol	29-44	C-C motif chemokine ligand 2	Homo sapiens	77-82
26492523-12	2016	In addition, 5z-7-oxozeaenol, LY294002, U0126 and aspirin prevented the IL-1beta-induced MCP-1 secretion of pulp cells.	5-7-oxo-zeaenol	13-28	interleukin 1 beta	Mus musculus	72-80
26492523-12	2016	In addition, 5z-7-oxozeaenol, LY294002, U0126 and aspirin prevented the IL-1beta-induced MCP-1 secretion of pulp cells.	5-7-oxo-zeaenol	13-28	mast cell protease 1	Mus musculus	89-94
26481152-0	2015	Isolation, semisynthesis, covalent docking and transforming growth factor beta-activated kinase 1 (TAK1)-inhibitory activities of (5Z)-7-oxozeaenol analogues.	5-7-oxo-zeaenol	130-147	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	47-97
26227222-3	2016	The TAK1 selective inhibitor 5Z-7-oxozeaenol has been widely studied in cancer therapy.	5-7-oxo-zeaenol	29-44	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	4-8
26227222-7	2016	Western blotting analysis verified that TAK1 inhibition by 5Z-7-oxozeaenol completely blocked JNK, p38, Erk, IKK, and IkappaB phosphorylation, which was almost instantly activated by TAK1 both directly or indirectly.	5-7-oxo-zeaenol	59-74	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	40-44
26227222-7	2016	Western blotting analysis verified that TAK1 inhibition by 5Z-7-oxozeaenol completely blocked JNK, p38, Erk, IKK, and IkappaB phosphorylation, which was almost instantly activated by TAK1 both directly or indirectly.	5-7-oxo-zeaenol	59-74	mitogen-activated protein kinase 14	Homo sapiens	99-102
26227222-7	2016	Western blotting analysis verified that TAK1 inhibition by 5Z-7-oxozeaenol completely blocked JNK, p38, Erk, IKK, and IkappaB phosphorylation, which was almost instantly activated by TAK1 both directly or indirectly.	5-7-oxo-zeaenol	59-74	mitogen-activated protein kinase 1	Homo sapiens	104-107
26227222-7	2016	Western blotting analysis verified that TAK1 inhibition by 5Z-7-oxozeaenol completely blocked JNK, p38, Erk, IKK, and IkappaB phosphorylation, which was almost instantly activated by TAK1 both directly or indirectly.	5-7-oxo-zeaenol	59-74	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	183-187
26227222-10	2016	Collectively, our results indicated that the proteasome inhibitor bortezomib and the TAK1 inhibitor 5Z-7-oxozeaenol displayed synergy on inhibiting BL cell apoptosis by inhibiting NF-kappaB activity.	5-7-oxo-zeaenol	100-115	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	85-89
26227222-10	2016	Collectively, our results indicated that the proteasome inhibitor bortezomib and the TAK1 inhibitor 5Z-7-oxozeaenol displayed synergy on inhibiting BL cell apoptosis by inhibiting NF-kappaB activity.	5-7-oxo-zeaenol	100-115	nuclear factor kappa B subunit 1	Homo sapiens	180-189
26491199-4	2015	Blocking TAK1 kinase activity with a highly selective inhibitor (5z-7-oxozeaenol) attenuated the inducible phosphorylation of ERK occurring in response to these stimuli but had little or no effect on that of p38 MAPK or PI3K.	5-7-oxo-zeaenol	65-80	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	9-13
26491199-4	2015	Blocking TAK1 kinase activity with a highly selective inhibitor (5z-7-oxozeaenol) attenuated the inducible phosphorylation of ERK occurring in response to these stimuli but had little or no effect on that of p38 MAPK or PI3K.	5-7-oxo-zeaenol	65-80	mitogen-activated protein kinase 1	Homo sapiens	126-129
26318254-7	2016	Moreover, verproside attenuated TNF-alpha-induced MUC5AC transcription more effectively when combined with an IKK (BAY11-7082) or a TAK1 (5z-7-oxozeaenol) inhibitor than when administered alone.	5-7-oxo-zeaenol	138-153	tumor necrosis factor	Homo sapiens	32-41
26318254-7	2016	Moreover, verproside attenuated TNF-alpha-induced MUC5AC transcription more effectively when combined with an IKK (BAY11-7082) or a TAK1 (5z-7-oxozeaenol) inhibitor than when administered alone.	5-7-oxo-zeaenol	138-153	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	50-56
26481152-0	2015	Isolation, semisynthesis, covalent docking and transforming growth factor beta-activated kinase 1 (TAK1)-inhibitory activities of (5Z)-7-oxozeaenol analogues.	5-7-oxo-zeaenol	130-147	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	99-103
26269654-10	2015	Using a combination of adenoviruses encoding dominant-negative TAK1 and the TAK1 inhibitor 5Z-7-oxozeaenol, we demonstrated that the TRAF3-mediated activation of ischemic cascades was TAK1-dependent.	5-7-oxo-zeaenol	91-106	mitogen-activated protein kinase kinase kinase 7	Mus musculus	76-80
26823762-9	2015	In vitro, 5Z-7-oxozeaenol, a selective TAK1 inhibitor, significantly inhibited the proliferation and invasion and promoted the apoptosis of thyroid cancer cells, possibly due to its inhibition of the activation of the nuclear factor-kappaB (NF-kappaB) signaling pathway.	5-7-oxo-zeaenol	10-25	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	39-43
26823762-9	2015	In vitro, 5Z-7-oxozeaenol, a selective TAK1 inhibitor, significantly inhibited the proliferation and invasion and promoted the apoptosis of thyroid cancer cells, possibly due to its inhibition of the activation of the nuclear factor-kappaB (NF-kappaB) signaling pathway.	5-7-oxo-zeaenol	10-25	nuclear factor kappa B subunit 1	Homo sapiens	218-239
26823762-9	2015	In vitro, 5Z-7-oxozeaenol, a selective TAK1 inhibitor, significantly inhibited the proliferation and invasion and promoted the apoptosis of thyroid cancer cells, possibly due to its inhibition of the activation of the nuclear factor-kappaB (NF-kappaB) signaling pathway.	5-7-oxo-zeaenol	10-25	nuclear factor kappa B subunit 1	Homo sapiens	241-250
26459028-3	2015	Administration of 5Z-7-oxozeaenol (OZ), a TAK1 inhibitor, decreased the incidence and delayed the onset of autoimmune diabetes in both spontaneous and accelerated (cyclophosphamide-induced) experimental NOD mice.	5-7-oxo-zeaenol	18-33	mitogen-activated protein kinase kinase kinase 7	Mus musculus	42-46
26291056-3	2015	METHODS: TAK1 kinase activity was inhibited in FLO-1 and KYAE-1 oesophageal adenocarcinoma cells using (5Z)-7-oxozeaenol.	5-7-oxo-zeaenol	103-120	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	9-13
26291056-6	2015	RESULTS: In vitro, (5Z)-7-oxozeaenol significantly reduced BIRC3 expression in FLO-1 and KYAE-1 cells.	5-7-oxo-zeaenol	19-36	baculoviral IAP repeat containing 3	Homo sapiens	59-64
26269654-10	2015	Using a combination of adenoviruses encoding dominant-negative TAK1 and the TAK1 inhibitor 5Z-7-oxozeaenol, we demonstrated that the TRAF3-mediated activation of ischemic cascades was TAK1-dependent.	5-7-oxo-zeaenol	91-106	TNF receptor-associated factor 3	Mus musculus	133-138
26269654-10	2015	Using a combination of adenoviruses encoding dominant-negative TAK1 and the TAK1 inhibitor 5Z-7-oxozeaenol, we demonstrated that the TRAF3-mediated activation of ischemic cascades was TAK1-dependent.	5-7-oxo-zeaenol	91-106	mitogen-activated protein kinase kinase kinase 7	Mus musculus	76-80
26114584-1	2015	Transforming growth factor beta-activated kinase 1 (TAK1) is critical for survival of many KRAS mutated colorectal cancer cells, and TAK1 inhibition with 5Z-7-oxozeaenol has been associated with oxidative stress leading to tumor cell killing.	5-7-oxo-zeaenol	154-169	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	133-137
26100626-0	2015	TGFbeta-activated Kinase 1 (TAK1) Inhibition by 5Z-7-Oxozeaenol Attenuates Early Brain Injury after Experimental Subarachnoid Hemorrhage.	5-7-oxo-zeaenol	48-63	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	0-26
26100626-0	2015	TGFbeta-activated Kinase 1 (TAK1) Inhibition by 5Z-7-Oxozeaenol Attenuates Early Brain Injury after Experimental Subarachnoid Hemorrhage.	5-7-oxo-zeaenol	48-63	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	28-32
26100626-4	2015	Intracerebroventricular injection of a selective TAK1 inhibitor (10 min post-SAH), 5Z-7-oxozeaenol (OZ), significantly reduced the levels of TAK1 and p-TAK1 at 24 h post-SAH.	5-7-oxo-zeaenol	83-98	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	49-53
26100626-4	2015	Intracerebroventricular injection of a selective TAK1 inhibitor (10 min post-SAH), 5Z-7-oxozeaenol (OZ), significantly reduced the levels of TAK1 and p-TAK1 at 24 h post-SAH.	5-7-oxo-zeaenol	83-98	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	141-145
26100626-4	2015	Intracerebroventricular injection of a selective TAK1 inhibitor (10 min post-SAH), 5Z-7-oxozeaenol (OZ), significantly reduced the levels of TAK1 and p-TAK1 at 24 h post-SAH.	5-7-oxo-zeaenol	83-98	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	141-145
26114584-3	2015	Consistent with TAK1 inhibition being causally related to thiol-mediated oxidative stress, 10mM N-acetylcysteine (NAC) partially reversed the growth inhibitory effects of 5Z-7-oxozeaenol.	5-7-oxo-zeaenol	171-186	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	16-20
26114584-6	2015	In contrast, pre-treatment of cells with auranofin (Au) to inhibit thioredoxin reductase activity significantly increased levels of oxidized thioredoxin as well as sensitized cells to 5Z-7-oxozeaenol-induced growth inhibition and clonogenic cell killing.	5-7-oxo-zeaenol	184-199	thioredoxin	Homo sapiens	67-78
25998883-6	2015	Moreover, blockage of TAK1 using siRNA oligos or TAK1 inhibitor 5Z-7-oxozeaenol significantly attenuated TCDD-induced astrocyte activation as well as the release of TNF-alpha.	5-7-oxo-zeaenol	64-79	mitogen activated protein kinase kinase kinase 7	Rattus norvegicus	22-26
25625840-9	2015	Intrathecal administration of 5Z-7-oxozeaenol (OZ), a selective TAK1 inhibitor, attenuated the loss of morphine analgesic potency and morphine-induced TAK1 up-regulation.	5-7-oxo-zeaenol	30-45	mitogen activated protein kinase kinase kinase 7	Rattus norvegicus	64-68
25625840-9	2015	Intrathecal administration of 5Z-7-oxozeaenol (OZ), a selective TAK1 inhibitor, attenuated the loss of morphine analgesic potency and morphine-induced TAK1 up-regulation.	5-7-oxo-zeaenol	30-45	mitogen activated protein kinase kinase kinase 7	Rattus norvegicus	151-155
25625840-14	2015	Modulation of TAK1 activation by the selective inhibitor OZ in the lumbar spinal cord may prove to be an attractive adjuvant therapy to attenuate such tolerance.	5-7-oxo-zeaenol	57-59	mitogen activated protein kinase kinase kinase 7	Rattus norvegicus	14-18
25998883-6	2015	Moreover, blockage of TAK1 using siRNA oligos or TAK1 inhibitor 5Z-7-oxozeaenol significantly attenuated TCDD-induced astrocyte activation as well as the release of TNF-alpha.	5-7-oxo-zeaenol	64-79	mitogen activated protein kinase kinase kinase 7	Rattus norvegicus	49-53
26020972-3	2015	AICAR increased p38 MAPK activation and the phagocytosis of apoptotic cells by macrophages, which were inhibited by the p38 MAPK inhibitor, SB203580, the TGF-beta-activated kinase 1 (TAK1) inhibitor, (5Z)-7-oxozeaenol, and siRNA-mediated knock-down of p38alpha.	5-7-oxo-zeaenol	200-217	mitogen-activated protein kinase 14	Mus musculus	16-19
26020972-3	2015	AICAR increased p38 MAPK activation and the phagocytosis of apoptotic cells by macrophages, which were inhibited by the p38 MAPK inhibitor, SB203580, the TGF-beta-activated kinase 1 (TAK1) inhibitor, (5Z)-7-oxozeaenol, and siRNA-mediated knock-down of p38alpha.	5-7-oxo-zeaenol	200-217	mitogen-activated protein kinase kinase kinase 7	Mus musculus	154-181
26020972-3	2015	AICAR increased p38 MAPK activation and the phagocytosis of apoptotic cells by macrophages, which were inhibited by the p38 MAPK inhibitor, SB203580, the TGF-beta-activated kinase 1 (TAK1) inhibitor, (5Z)-7-oxozeaenol, and siRNA-mediated knock-down of p38alpha.	5-7-oxo-zeaenol	200-217	mitogen-activated protein kinase kinase kinase 7	Mus musculus	183-187
25927238-4	2015	Previously, we used the TAK1 inhibitor (5Z)-7-Oxozeaenol to show that, in dermal fibroblasts, the non-canonical TAK1 pathway mediates the ability of TGFbeta1 to induce genes promoting tissue remodeling and repair.	5-7-oxo-zeaenol	39-56	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	24-28
25753204-4	2015	TAK1 inhibitors, including LYTAK1 and 5Z-7-oxozeaenol (57-OZ), inhibited Dex-induced apoptosis of MLO-Y4 and OB-6 cells.	5-7-oxo-zeaenol	38-53	mitogen-activated protein kinase kinase kinase 7	Mus musculus	0-4
25927238-4	2015	Previously, we used the TAK1 inhibitor (5Z)-7-Oxozeaenol to show that, in dermal fibroblasts, the non-canonical TAK1 pathway mediates the ability of TGFbeta1 to induce genes promoting tissue remodeling and repair.	5-7-oxo-zeaenol	39-56	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	112-116
25927238-4	2015	Previously, we used the TAK1 inhibitor (5Z)-7-Oxozeaenol to show that, in dermal fibroblasts, the non-canonical TAK1 pathway mediates the ability of TGFbeta1 to induce genes promoting tissue remodeling and repair.	5-7-oxo-zeaenol	39-56	transforming growth factor beta 1	Homo sapiens	149-157
25927238-6	2015	Herein, we show that, in gingival fibroblasts, (5Z)-7-Oxozeaenol blocks the ability of TGFbeta1 to induce expression of the pro-fibrotic mediator CCN2 (connective tissue growth factor, CTGF) and type I collagen protein.	5-7-oxo-zeaenol	47-64	transforming growth factor beta 1	Homo sapiens	87-95
25927238-6	2015	Herein, we show that, in gingival fibroblasts, (5Z)-7-Oxozeaenol blocks the ability of TGFbeta1 to induce expression of the pro-fibrotic mediator CCN2 (connective tissue growth factor, CTGF) and type I collagen protein.	5-7-oxo-zeaenol	47-64	cellular communication network factor 2	Homo sapiens	146-150
25927238-6	2015	Herein, we show that, in gingival fibroblasts, (5Z)-7-Oxozeaenol blocks the ability of TGFbeta1 to induce expression of the pro-fibrotic mediator CCN2 (connective tissue growth factor, CTGF) and type I collagen protein.	5-7-oxo-zeaenol	47-64	cellular communication network factor 2	Homo sapiens	185-189
25927238-7	2015	Moreover, genome-wide expression profiling revealed that, in gingival fibroblasts, (5Z)-7-Oxozeaenol reduces the ability of TGFbeta1 to induce mRNA expression of essentially all TGFbeta1-responsive genes (139/147), including those involved with a hyperproliferative response.	5-7-oxo-zeaenol	83-100	transforming growth factor beta 1	Homo sapiens	124-132
25927238-7	2015	Moreover, genome-wide expression profiling revealed that, in gingival fibroblasts, (5Z)-7-Oxozeaenol reduces the ability of TGFbeta1 to induce mRNA expression of essentially all TGFbeta1-responsive genes (139/147), including those involved with a hyperproliferative response.	5-7-oxo-zeaenol	83-100	transforming growth factor beta 1	Homo sapiens	178-186
25452303-7	2015	LPS-injected CPEB KO mice secrete prodigious amounts of IL-6 and other proinflammatory cytokines and exhibit hypersensitivity to endotoxic shock; these effects are mitigated when the animals are also injected with (5Z)-7-oxozeaenol, a potent and specific inhibitor of TAK1.	5-7-oxo-zeaenol	214-231	cytoplasmic polyadenylation element binding protein 1	Mus musculus	13-17
25557171-6	2015	TAK1 inhibitor 5Z-7-Oxozeaenol (5Z-O) inhibited TAK1 activity, suppressed downstream signaling pathways including p38, IkappaB kinase (IKK) and c-Jun N-terminal kinase (JNK) and reduced CCR7 expression in metastatic MDA-MB-231 cells.	5-7-oxo-zeaenol	15-30	mitogen-activated protein kinase 14	Homo sapiens	114-117
25557171-6	2015	TAK1 inhibitor 5Z-7-Oxozeaenol (5Z-O) inhibited TAK1 activity, suppressed downstream signaling pathways including p38, IkappaB kinase (IKK) and c-Jun N-terminal kinase (JNK) and reduced CCR7 expression in metastatic MDA-MB-231 cells.	5-7-oxo-zeaenol	15-30	mitogen-activated protein kinase 8	Homo sapiens	144-167
25557171-6	2015	TAK1 inhibitor 5Z-7-Oxozeaenol (5Z-O) inhibited TAK1 activity, suppressed downstream signaling pathways including p38, IkappaB kinase (IKK) and c-Jun N-terminal kinase (JNK) and reduced CCR7 expression in metastatic MDA-MB-231 cells.	5-7-oxo-zeaenol	15-30	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	0-4
25557171-6	2015	TAK1 inhibitor 5Z-7-Oxozeaenol (5Z-O) inhibited TAK1 activity, suppressed downstream signaling pathways including p38, IkappaB kinase (IKK) and c-Jun N-terminal kinase (JNK) and reduced CCR7 expression in metastatic MDA-MB-231 cells.	5-7-oxo-zeaenol	15-30	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	48-52
25557171-6	2015	TAK1 inhibitor 5Z-7-Oxozeaenol (5Z-O) inhibited TAK1 activity, suppressed downstream signaling pathways including p38, IkappaB kinase (IKK) and c-Jun N-terminal kinase (JNK) and reduced CCR7 expression in metastatic MDA-MB-231 cells.	5-7-oxo-zeaenol	15-30	mitogen-activated protein kinase 8	Homo sapiens	169-172
25557171-6	2015	TAK1 inhibitor 5Z-7-Oxozeaenol (5Z-O) inhibited TAK1 activity, suppressed downstream signaling pathways including p38, IkappaB kinase (IKK) and c-Jun N-terminal kinase (JNK) and reduced CCR7 expression in metastatic MDA-MB-231 cells.	5-7-oxo-zeaenol	15-30	C-C motif chemokine receptor 7	Homo sapiens	186-190
25557171-6	2015	TAK1 inhibitor 5Z-7-Oxozeaenol (5Z-O) inhibited TAK1 activity, suppressed downstream signaling pathways including p38, IkappaB kinase (IKK) and c-Jun N-terminal kinase (JNK) and reduced CCR7 expression in metastatic MDA-MB-231 cells.	5-7-oxo-zeaenol	32-36	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	0-4
25557171-6	2015	TAK1 inhibitor 5Z-7-Oxozeaenol (5Z-O) inhibited TAK1 activity, suppressed downstream signaling pathways including p38, IkappaB kinase (IKK) and c-Jun N-terminal kinase (JNK) and reduced CCR7 expression in metastatic MDA-MB-231 cells.	5-7-oxo-zeaenol	32-36	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	48-52
25557171-6	2015	TAK1 inhibitor 5Z-7-Oxozeaenol (5Z-O) inhibited TAK1 activity, suppressed downstream signaling pathways including p38, IkappaB kinase (IKK) and c-Jun N-terminal kinase (JNK) and reduced CCR7 expression in metastatic MDA-MB-231 cells.	5-7-oxo-zeaenol	32-36	mitogen-activated protein kinase 14	Homo sapiens	114-117
25557171-6	2015	TAK1 inhibitor 5Z-7-Oxozeaenol (5Z-O) inhibited TAK1 activity, suppressed downstream signaling pathways including p38, IkappaB kinase (IKK) and c-Jun N-terminal kinase (JNK) and reduced CCR7 expression in metastatic MDA-MB-231 cells.	5-7-oxo-zeaenol	32-36	mitogen-activated protein kinase 8	Homo sapiens	144-167
25557171-6	2015	TAK1 inhibitor 5Z-7-Oxozeaenol (5Z-O) inhibited TAK1 activity, suppressed downstream signaling pathways including p38, IkappaB kinase (IKK) and c-Jun N-terminal kinase (JNK) and reduced CCR7 expression in metastatic MDA-MB-231 cells.	5-7-oxo-zeaenol	32-36	mitogen-activated protein kinase 8	Homo sapiens	169-172
25557171-6	2015	TAK1 inhibitor 5Z-7-Oxozeaenol (5Z-O) inhibited TAK1 activity, suppressed downstream signaling pathways including p38, IkappaB kinase (IKK) and c-Jun N-terminal kinase (JNK) and reduced CCR7 expression in metastatic MDA-MB-231 cells.	5-7-oxo-zeaenol	32-36	C-C motif chemokine receptor 7	Homo sapiens	186-190
25557171-7	2015	In addition, 5Z-O repressed NF-kappaB- and c-JUN-mediated transcription of CCR7 gene.	5-7-oxo-zeaenol	13-17	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	43-48
25557171-7	2015	In addition, 5Z-O repressed NF-kappaB- and c-JUN-mediated transcription of CCR7 gene.	5-7-oxo-zeaenol	13-17	C-C motif chemokine receptor 7	Homo sapiens	75-79
26584289-9	2015	5Z-7-oxozeaenol and SB203580, which block TAK1 and p38 kinase respectively, abrogated the LTB4 inhibitory effect on L-type calcium channels.	5-7-oxo-zeaenol	0-15	mitogen activated protein kinase kinase kinase 7	Rattus norvegicus	42-46
26584289-9	2015	5Z-7-oxozeaenol and SB203580, which block TAK1 and p38 kinase respectively, abrogated the LTB4 inhibitory effect on L-type calcium channels.	5-7-oxo-zeaenol	0-15	mitogen activated protein kinase 14	Rattus norvegicus	51-54
25277189-6	2014	Conversely, suppression of TAK1 activity by point mutation at Ser412, RNAi mediated gene knockdown or TAK1 specific inhibitor ((5Z) -7-Oxozeaenol) remarkably impairs tumor growth and metastasis in ovarian cancer in vitro and in vivo.	5-7-oxo-zeaenol	127-145	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	27-31
25462874-10	2014	Upstream activation of AMPK-induced neuronal loss was tested by treating cultures with AICAR (10-3 M) in the presence of TAK1 inhibitor (5Z)-7-Oxozeaenol (10-6 M).	5-7-oxo-zeaenol	137-153	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	23-27
25462874-10	2014	Upstream activation of AMPK-induced neuronal loss was tested by treating cultures with AICAR (10-3 M) in the presence of TAK1 inhibitor (5Z)-7-Oxozeaenol (10-6 M).	5-7-oxo-zeaenol	137-153	mitogen activated protein kinase kinase kinase 7	Rattus norvegicus	121-125
25462874-14	2014	LPS-, AICAR- and metformin-,but not A-769662-, induced neuronal losses were inhibited by presence of compound C. LPS, AICAR or metformin exposure increased the relative number of VIP-IR neurons; co-treatment with (5Z)-7-Oxozeaenol or compound C reversed the relative increase in VIP-IR neurons induced by LPS.	5-7-oxo-zeaenol	213-230	vasoactive intestinal peptide	Rattus norvegicus	179-182
26151454-10	2015	Both 5Z-7-Oxozeaenol and BAY 11-7082 significantly abrogated dsRNA-induced IL-32 production.	5-7-oxo-zeaenol	5-20	interleukin 32	Homo sapiens	75-80
25277189-6	2014	Conversely, suppression of TAK1 activity by point mutation at Ser412, RNAi mediated gene knockdown or TAK1 specific inhibitor ((5Z) -7-Oxozeaenol) remarkably impairs tumor growth and metastasis in ovarian cancer in vitro and in vivo.	5-7-oxo-zeaenol	127-145	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	102-106
25050617-5	2014	In vivo, pharmacological inhibition of TAK1 with 5Z-7-oxozeaenol blocked the injury-induced phosphorylation of both TAK1 (Thr187) and NF-kB/p65 (Ser536), associated with marked inhibition of superoxide production, 3-nitrotyrosine, and MCP-1 in the injured arteries.	5-7-oxo-zeaenol	49-64	mitogen-activated protein kinase kinase kinase 7	Mus musculus	39-43
25118260-3	2014	METHODS: Cultured human RPE cells were treated with the TAK1 inhibitor 5Z-7-oxozeaenol for 1 hour, and then treated with 200 muM hydrogen peroxide for 1 hour.	5-7-oxo-zeaenol	71-86	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	56-60
25050617-5	2014	In vivo, pharmacological inhibition of TAK1 with 5Z-7-oxozeaenol blocked the injury-induced phosphorylation of both TAK1 (Thr187) and NF-kB/p65 (Ser536), associated with marked inhibition of superoxide production, 3-nitrotyrosine, and MCP-1 in the injured arteries.	5-7-oxo-zeaenol	49-64	mitogen-activated protein kinase kinase kinase 7	Mus musculus	116-120
25050617-5	2014	In vivo, pharmacological inhibition of TAK1 with 5Z-7-oxozeaenol blocked the injury-induced phosphorylation of both TAK1 (Thr187) and NF-kB/p65 (Ser536), associated with marked inhibition of superoxide production, 3-nitrotyrosine, and MCP-1 in the injured arteries.	5-7-oxo-zeaenol	49-64	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	140-143
25050617-5	2014	In vivo, pharmacological inhibition of TAK1 with 5Z-7-oxozeaenol blocked the injury-induced phosphorylation of both TAK1 (Thr187) and NF-kB/p65 (Ser536), associated with marked inhibition of superoxide production, 3-nitrotyrosine, and MCP-1 in the injured arteries.	5-7-oxo-zeaenol	49-64	mast cell protease 1	Mus musculus	235-240
25050617-6	2014	Cell culture experiments demonstrated that either siRNA knockdown or 5Z-7-oxozeaenol inhibition of TAK1 significantly attenuated NADPH oxidase activation and superoxide production induced by CD40L/CD40 stimulation.	5-7-oxo-zeaenol	69-84	mitogen-activated protein kinase kinase kinase 7	Mus musculus	99-103
25050617-6	2014	Cell culture experiments demonstrated that either siRNA knockdown or 5Z-7-oxozeaenol inhibition of TAK1 significantly attenuated NADPH oxidase activation and superoxide production induced by CD40L/CD40 stimulation.	5-7-oxo-zeaenol	69-84	CD40 ligand	Mus musculus	191-196
25050617-6	2014	Cell culture experiments demonstrated that either siRNA knockdown or 5Z-7-oxozeaenol inhibition of TAK1 significantly attenuated NADPH oxidase activation and superoxide production induced by CD40L/CD40 stimulation.	5-7-oxo-zeaenol	69-84	CD40 antigen	Mus musculus	191-195
23700229-0	2013	TAK1 inhibitor 5Z-7-oxozeaenol sensitizes neuroblastoma to chemotherapy.	5-7-oxo-zeaenol	15-30	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	0-4
24874739-6	2014	Indeed, the TAK1 inhibitor 5Z-7-oxozeaenol as well as the ectopic expression of a dominant-negative mutant of TAK1 or TRAF2, an upstream molecule of TAK1, inhibited Nef-induced signaling activation and M1-like phenotypic differentiation of M2-MPhi.	5-7-oxo-zeaenol	27-42	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	12-16
24874739-6	2014	Indeed, the TAK1 inhibitor 5Z-7-oxozeaenol as well as the ectopic expression of a dominant-negative mutant of TAK1 or TRAF2, an upstream molecule of TAK1, inhibited Nef-induced signaling activation and M1-like phenotypic differentiation of M2-MPhi.	5-7-oxo-zeaenol	27-42	S100 calcium binding protein B	Homo sapiens	165-168
24486706-5	2014	An inhibitor of the upstream kinase TGF-beta-activated kinase (TAK1), (5z)-7-oxozeaenol, abolished the phosphorylation of ACC and p38 MAPK.	5-7-oxo-zeaenol	70-87	mitogen-activated protein kinase kinase kinase 7	Mus musculus	63-67
24486706-5	2014	An inhibitor of the upstream kinase TGF-beta-activated kinase (TAK1), (5z)-7-oxozeaenol, abolished the phosphorylation of ACC and p38 MAPK.	5-7-oxo-zeaenol	70-87	mitogen-activated protein kinase 14	Mus musculus	130-138
23700229-4	2013	Using a panel of neuroblastoma cell lines, we found that TAK1 inhibitor 5Z-7-oxozeaenol significantly augmented the cytotoxic effects of doxorubicin (Dox) and etoposide (VP-16) on neuroblastoma cell lines.	5-7-oxo-zeaenol	72-87	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	57-61
23700229-4	2013	Using a panel of neuroblastoma cell lines, we found that TAK1 inhibitor 5Z-7-oxozeaenol significantly augmented the cytotoxic effects of doxorubicin (Dox) and etoposide (VP-16) on neuroblastoma cell lines.	5-7-oxo-zeaenol	72-87	host cell factor C1	Homo sapiens	170-175
23485590-6	2013	The effects of specific inhibition of the TAK1 pathway by 5Z-7-oxozeaenol (OZ, intracerebroventricular injection at 10min post-trauma) on histopathological and behavioral outcomes in rats were assessed at 24h post injury.	5-7-oxo-zeaenol	58-73	mitogen activated protein kinase kinase kinase 7	Rattus norvegicus	42-46
23742763-7	2013	The selective TAK1 inhibitor 5Z-7-oxozeaenol (5Z-7) exacerbated the loss of cell viability, whereas the ASK1 inhibitor NQDI-1 completely prevented caspase activation and cell death.	5-7-oxo-zeaenol	29-44	mitogen-activated protein kinase kinase kinase 7	Mus musculus	14-18
23272696-3	2013	Here, we show that, in addition to its kinase activity, TAK1 has intrinsic ATPase activity, that (5Z)-7-Oxozeaenol irreversibly inhibits TAK1, and that sensitivity to (5Z)-7-Oxozeaenol inhibition in hematological cancer cell lines is NRAS mutation status and TAK1 pathway dependent.	5-7-oxo-zeaenol	167-184	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	56-60
23272696-0	2013	Mechanism and in vitro pharmacology of TAK1 inhibition by (5Z)-7-Oxozeaenol.	5-7-oxo-zeaenol	58-75	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	39-43
23272696-3	2013	Here, we show that, in addition to its kinase activity, TAK1 has intrinsic ATPase activity, that (5Z)-7-Oxozeaenol irreversibly inhibits TAK1, and that sensitivity to (5Z)-7-Oxozeaenol inhibition in hematological cancer cell lines is NRAS mutation status and TAK1 pathway dependent.	5-7-oxo-zeaenol	97-114	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	56-60
23272696-3	2013	Here, we show that, in addition to its kinase activity, TAK1 has intrinsic ATPase activity, that (5Z)-7-Oxozeaenol irreversibly inhibits TAK1, and that sensitivity to (5Z)-7-Oxozeaenol inhibition in hematological cancer cell lines is NRAS mutation status and TAK1 pathway dependent.	5-7-oxo-zeaenol	97-114	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	137-141
23272696-3	2013	Here, we show that, in addition to its kinase activity, TAK1 has intrinsic ATPase activity, that (5Z)-7-Oxozeaenol irreversibly inhibits TAK1, and that sensitivity to (5Z)-7-Oxozeaenol inhibition in hematological cancer cell lines is NRAS mutation status and TAK1 pathway dependent.	5-7-oxo-zeaenol	97-114	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	137-141
23272696-3	2013	Here, we show that, in addition to its kinase activity, TAK1 has intrinsic ATPase activity, that (5Z)-7-Oxozeaenol irreversibly inhibits TAK1, and that sensitivity to (5Z)-7-Oxozeaenol inhibition in hematological cancer cell lines is NRAS mutation status and TAK1 pathway dependent.	5-7-oxo-zeaenol	167-184	NRAS proto-oncogene, GTPase	Homo sapiens	234-238
23272696-4	2013	X-ray crystallographic and mass spectrometric studies showed that (5Z)-7-Oxozeaenol forms a covalent complex with TAK1.	5-7-oxo-zeaenol	66-83	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	114-118
23272696-5	2013	Detailed biochemical characterization revealed that (5Z)-7-Oxozeaenol inhibited both the kinase and the ATPase activity of TAK1 following a bi-phase kinetics, consistent with the irreversible inhibition mechanism.	5-7-oxo-zeaenol	52-69	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	123-127
23272696-6	2013	In DoHH2 cells, (5Z)-7-Oxozeaenol potently inhibited the p38 phosphorylation driven by TAK1, and the inhibition lasted over 6 h after withdrawal of (5Z)-7-Oxozeaenol.	5-7-oxo-zeaenol	16-33	mitogen-activated protein kinase 14	Homo sapiens	57-60
23272696-6	2013	In DoHH2 cells, (5Z)-7-Oxozeaenol potently inhibited the p38 phosphorylation driven by TAK1, and the inhibition lasted over 6 h after withdrawal of (5Z)-7-Oxozeaenol.	5-7-oxo-zeaenol	16-33	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	87-91
23272696-7	2013	Profiling (5Z)-7-Oxozeaenol in a panel of hematological cancer cells showed that sensitive cell lines tended to carry NRAS mutations and that genes in TAK1 regulated pathways were enriched in sensitive cell lines.	5-7-oxo-zeaenol	10-27	NRAS proto-oncogene, GTPase	Homo sapiens	118-122
23272696-7	2013	Profiling (5Z)-7-Oxozeaenol in a panel of hematological cancer cells showed that sensitive cell lines tended to carry NRAS mutations and that genes in TAK1 regulated pathways were enriched in sensitive cell lines.	5-7-oxo-zeaenol	10-27	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	151-155
22523282-8	2012	CSE-induced ERK-1/2 phosphorylation and Ikappa-Balpha degradation were both inhibited by pretreatment with the specific TAK1 inhibitor LL-Z-1640-2 (5Z-7-oxozeaenol; 100 nM).	5-7-oxo-zeaenol	148-163	mitogen-activated protein kinase 1	Homo sapiens	12-19
23022457-3	2013	Indeed, a recent publication in Experimental Neurology confirmed that TAK1 inhibition by 5Z-7-oxozeaenol is neuroprotective.	5-7-oxo-zeaenol	89-104	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	70-74
22628200-12	2012	5Z-7-oxozeaenol and dorsomorphin eliminated the BMP2-induced increase in DNA fragmentation in NHOst, suggesting roles for TAB/TAK1 and Smad signaling.	5-7-oxo-zeaenol	0-15	bone morphogenetic protein 2	Homo sapiens	48-52
22628200-12	2012	5Z-7-oxozeaenol and dorsomorphin eliminated the BMP2-induced increase in DNA fragmentation in NHOst, suggesting roles for TAB/TAK1 and Smad signaling.	5-7-oxo-zeaenol	0-15	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	126-130
22683931-5	2012	The TAK1 inhibitor 5Z-7-oxozeaenol was injected either intracerebroventricularly or intraperitoneally at various doses and infarct size and functional outcome after long term survival was assessed.	5-7-oxo-zeaenol	19-34	mitogen-activated protein kinase kinase kinase 7	Mus musculus	4-8
22523282-8	2012	CSE-induced ERK-1/2 phosphorylation and Ikappa-Balpha degradation were both inhibited by pretreatment with the specific TAK1 inhibitor LL-Z-1640-2 (5Z-7-oxozeaenol; 100 nM).	5-7-oxo-zeaenol	148-163	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	120-124
21873447-6	2011	Platelet-derived growth factor- (PDGF; 10 ng/ml) and fetal bovine serum (5%)-induced increases in DNA synthesis and cell number in bovine and human cells were significantly inhibited by pretreatment with the specific TAK1 inhibitor LL-Z-1640-2 (5Z-7-oxozeaenol; 100 nM).	5-7-oxo-zeaenol	245-260	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	217-221
22753698-3	2012	The effects of (5Z)-7-oxozeaenol on the expression of the nuclear factor kappa B (NF-kappaB) p65, p50, IkappaB kinase (IKKalpha), IKKbeta and caspase-7 were analyzed by western blot.	5-7-oxo-zeaenol	15-32	nuclear factor kappa B subunit 1	Homo sapiens	58-80
22753698-3	2012	The effects of (5Z)-7-oxozeaenol on the expression of the nuclear factor kappa B (NF-kappaB) p65, p50, IkappaB kinase (IKKalpha), IKKbeta and caspase-7 were analyzed by western blot.	5-7-oxo-zeaenol	15-32	nuclear factor kappa B subunit 1	Homo sapiens	82-91
22753698-3	2012	The effects of (5Z)-7-oxozeaenol on the expression of the nuclear factor kappa B (NF-kappaB) p65, p50, IkappaB kinase (IKKalpha), IKKbeta and caspase-7 were analyzed by western blot.	5-7-oxo-zeaenol	15-32	RELA proto-oncogene, NF-kB subunit	Homo sapiens	93-96
22753698-6	2012	RESULTS: (5Z)-7-Oxozeaenol down-regulated NF-kappaB in a dose-dependent manner.	5-7-oxo-zeaenol	9-26	nuclear factor kappa B subunit 1	Homo sapiens	42-51
22753698-10	2012	(5Z)-7-Oxozeaenol also significantly enhanced apoptosis of treated cells, through the activation of caspase-7.	5-7-oxo-zeaenol	0-17	caspase 7	Homo sapiens	100-109
22753698-11	2012	CONCLUSION: Our findings suggest that (5Z)-7-oxozeaenol is a potent up-stream inhibitor of the NF-kappaB pathway, enhances the sensitivity of treated cells to apoptosis induced by ROS, and affects cell adhesion of MDA-MB-231 breast cancer cells.	5-7-oxo-zeaenol	38-55	nuclear factor kappa B subunit 1	Homo sapiens	95-104
22753724-5	2012	RESULTS: Cells treated with (5Z)-7-oxozeaenol exhibited down-regulation of NF-kappaB in a dose-dependent manner.	5-7-oxo-zeaenol	28-45	nuclear factor kappa B subunit 1	Homo sapiens	75-84
22753724-8	2012	The expression of caspase-3 and -7 was induced in (5Z)-7-oxozeaenol treated HeLa cells, in comparison with those treated with paclitaxel.	5-7-oxo-zeaenol	50-67	caspase 3	Homo sapiens	18-34
22753724-9	2012	CONCLUSION: Our findings suggest that (5Z)-7-oxozeaenol is a potent inhibitor of the NF-kappaB pathway and potentiates the production of ROS, as well as induces caspase-3 and -7 in HeLa and HT-29 cancer cells.	5-7-oxo-zeaenol	38-55	nuclear factor kappa B subunit 1	Homo sapiens	85-94
22753724-9	2012	CONCLUSION: Our findings suggest that (5Z)-7-oxozeaenol is a potent inhibitor of the NF-kappaB pathway and potentiates the production of ROS, as well as induces caspase-3 and -7 in HeLa and HT-29 cancer cells.	5-7-oxo-zeaenol	38-55	caspase 3	Homo sapiens	161-177
17348859-4	2007	We also show that RIP2 induces the activation of the protein kinase TAK1 (transforming-growth-factor-beta-activated kinase-1), that a dominant-negative mutant of TAK1 inhibits RIP2-induced activation of JNK (c-Jun N-terminal kinase) and p38alpha MAPK, and that signalling downstream of NOD2 or RIP2 is reduced by the TAK1 inhibitor (5Z)-7-oxozeaenol or in TAK1-deficient cells.	5-7-oxo-zeaenol	337-349	receptor interacting serine/threonine kinase 2	Homo sapiens	18-22
22171160-8	2011	All of these responses were blocked by the TAK1 inhibitor 5z-7-oxozeaenol (5z-OX).	5-7-oxo-zeaenol	58-73	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	43-47
22171160-8	2011	All of these responses were blocked by the TAK1 inhibitor 5z-7-oxozeaenol (5z-OX).	5-7-oxo-zeaenol	75-80	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	43-47
20014292-5	2010	The critical role for TAK1 in p38MAPK and NFkappaB activation was as well confirmed by the inhibition of p38MAPK and NFkappaB activity following 5Z-7-oxozeaenol, a selective inhibitor of TAK1.	5-7-oxo-zeaenol	145-160	mitogen-activated protein kinase kinase kinase 7	Mus musculus	22-26
20014292-5	2010	The critical role for TAK1 in p38MAPK and NFkappaB activation was as well confirmed by the inhibition of p38MAPK and NFkappaB activity following 5Z-7-oxozeaenol, a selective inhibitor of TAK1.	5-7-oxo-zeaenol	145-160	mitogen-activated protein kinase 14	Mus musculus	105-112
20014292-5	2010	The critical role for TAK1 in p38MAPK and NFkappaB activation was as well confirmed by the inhibition of p38MAPK and NFkappaB activity following 5Z-7-oxozeaenol, a selective inhibitor of TAK1.	5-7-oxo-zeaenol	145-160	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	117-125
20014292-5	2010	The critical role for TAK1 in p38MAPK and NFkappaB activation was as well confirmed by the inhibition of p38MAPK and NFkappaB activity following 5Z-7-oxozeaenol, a selective inhibitor of TAK1.	5-7-oxo-zeaenol	145-160	mitogen-activated protein kinase kinase kinase 7	Mus musculus	187-191
20014292-6	2010	Furthermore, it was found that TNF-alpha was completely blocked by 5Z-7-oxozeaenol in RAW 264.7 cells.	5-7-oxo-zeaenol	67-82	tumor necrosis factor	Mus musculus	31-40
20200282-7	2010	Blocking TAK1 kinase activity with a highly selective inhibitor (5z-7-oxozeaenol) attenuated the phosphorylation of nuclear and cytoplasmic IKKalpha/beta, IkappaB-alpha, and RelA, and also impaired IkappaB-alpha degradation and NF-kappaB DNA binding in activated neutrophils.	5-7-oxo-zeaenol	65-80	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	9-13
20200282-7	2010	Blocking TAK1 kinase activity with a highly selective inhibitor (5z-7-oxozeaenol) attenuated the phosphorylation of nuclear and cytoplasmic IKKalpha/beta, IkappaB-alpha, and RelA, and also impaired IkappaB-alpha degradation and NF-kappaB DNA binding in activated neutrophils.	5-7-oxo-zeaenol	65-80	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	140-153
20200282-7	2010	Blocking TAK1 kinase activity with a highly selective inhibitor (5z-7-oxozeaenol) attenuated the phosphorylation of nuclear and cytoplasmic IKKalpha/beta, IkappaB-alpha, and RelA, and also impaired IkappaB-alpha degradation and NF-kappaB DNA binding in activated neutrophils.	5-7-oxo-zeaenol	65-80	NFKB inhibitor alpha	Homo sapiens	155-168
20200282-7	2010	Blocking TAK1 kinase activity with a highly selective inhibitor (5z-7-oxozeaenol) attenuated the phosphorylation of nuclear and cytoplasmic IKKalpha/beta, IkappaB-alpha, and RelA, and also impaired IkappaB-alpha degradation and NF-kappaB DNA binding in activated neutrophils.	5-7-oxo-zeaenol	65-80	RELA proto-oncogene, NF-kB subunit	Homo sapiens	174-178
20200282-7	2010	Blocking TAK1 kinase activity with a highly selective inhibitor (5z-7-oxozeaenol) attenuated the phosphorylation of nuclear and cytoplasmic IKKalpha/beta, IkappaB-alpha, and RelA, and also impaired IkappaB-alpha degradation and NF-kappaB DNA binding in activated neutrophils.	5-7-oxo-zeaenol	65-80	NFKB inhibitor alpha	Homo sapiens	198-211
20200282-7	2010	Blocking TAK1 kinase activity with a highly selective inhibitor (5z-7-oxozeaenol) attenuated the phosphorylation of nuclear and cytoplasmic IKKalpha/beta, IkappaB-alpha, and RelA, and also impaired IkappaB-alpha degradation and NF-kappaB DNA binding in activated neutrophils.	5-7-oxo-zeaenol	65-80	nuclear factor kappa B subunit 1	Homo sapiens	228-237
17348859-4	2007	We also show that RIP2 induces the activation of the protein kinase TAK1 (transforming-growth-factor-beta-activated kinase-1), that a dominant-negative mutant of TAK1 inhibits RIP2-induced activation of JNK (c-Jun N-terminal kinase) and p38alpha MAPK, and that signalling downstream of NOD2 or RIP2 is reduced by the TAK1 inhibitor (5Z)-7-oxozeaenol or in TAK1-deficient cells.	5-7-oxo-zeaenol	337-349	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	68-72
17348859-4	2007	We also show that RIP2 induces the activation of the protein kinase TAK1 (transforming-growth-factor-beta-activated kinase-1), that a dominant-negative mutant of TAK1 inhibits RIP2-induced activation of JNK (c-Jun N-terminal kinase) and p38alpha MAPK, and that signalling downstream of NOD2 or RIP2 is reduced by the TAK1 inhibitor (5Z)-7-oxozeaenol or in TAK1-deficient cells.	5-7-oxo-zeaenol	337-349	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	74-124
17348859-4	2007	We also show that RIP2 induces the activation of the protein kinase TAK1 (transforming-growth-factor-beta-activated kinase-1), that a dominant-negative mutant of TAK1 inhibits RIP2-induced activation of JNK (c-Jun N-terminal kinase) and p38alpha MAPK, and that signalling downstream of NOD2 or RIP2 is reduced by the TAK1 inhibitor (5Z)-7-oxozeaenol or in TAK1-deficient cells.	5-7-oxo-zeaenol	337-349	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	162-166
17348859-4	2007	We also show that RIP2 induces the activation of the protein kinase TAK1 (transforming-growth-factor-beta-activated kinase-1), that a dominant-negative mutant of TAK1 inhibits RIP2-induced activation of JNK (c-Jun N-terminal kinase) and p38alpha MAPK, and that signalling downstream of NOD2 or RIP2 is reduced by the TAK1 inhibitor (5Z)-7-oxozeaenol or in TAK1-deficient cells.	5-7-oxo-zeaenol	337-349	receptor interacting serine/threonine kinase 2	Homo sapiens	176-180
17348859-4	2007	We also show that RIP2 induces the activation of the protein kinase TAK1 (transforming-growth-factor-beta-activated kinase-1), that a dominant-negative mutant of TAK1 inhibits RIP2-induced activation of JNK (c-Jun N-terminal kinase) and p38alpha MAPK, and that signalling downstream of NOD2 or RIP2 is reduced by the TAK1 inhibitor (5Z)-7-oxozeaenol or in TAK1-deficient cells.	5-7-oxo-zeaenol	337-349	mitogen-activated protein kinase 8	Homo sapiens	203-206
17348859-4	2007	We also show that RIP2 induces the activation of the protein kinase TAK1 (transforming-growth-factor-beta-activated kinase-1), that a dominant-negative mutant of TAK1 inhibits RIP2-induced activation of JNK (c-Jun N-terminal kinase) and p38alpha MAPK, and that signalling downstream of NOD2 or RIP2 is reduced by the TAK1 inhibitor (5Z)-7-oxozeaenol or in TAK1-deficient cells.	5-7-oxo-zeaenol	337-349	mitogen-activated protein kinase 8	Homo sapiens	208-231
17348859-4	2007	We also show that RIP2 induces the activation of the protein kinase TAK1 (transforming-growth-factor-beta-activated kinase-1), that a dominant-negative mutant of TAK1 inhibits RIP2-induced activation of JNK (c-Jun N-terminal kinase) and p38alpha MAPK, and that signalling downstream of NOD2 or RIP2 is reduced by the TAK1 inhibitor (5Z)-7-oxozeaenol or in TAK1-deficient cells.	5-7-oxo-zeaenol	337-349	receptor interacting serine/threonine kinase 2	Homo sapiens	176-180
17348859-4	2007	We also show that RIP2 induces the activation of the protein kinase TAK1 (transforming-growth-factor-beta-activated kinase-1), that a dominant-negative mutant of TAK1 inhibits RIP2-induced activation of JNK (c-Jun N-terminal kinase) and p38alpha MAPK, and that signalling downstream of NOD2 or RIP2 is reduced by the TAK1 inhibitor (5Z)-7-oxozeaenol or in TAK1-deficient cells.	5-7-oxo-zeaenol	337-349	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	162-166
17348859-4	2007	We also show that RIP2 induces the activation of the protein kinase TAK1 (transforming-growth-factor-beta-activated kinase-1), that a dominant-negative mutant of TAK1 inhibits RIP2-induced activation of JNK (c-Jun N-terminal kinase) and p38alpha MAPK, and that signalling downstream of NOD2 or RIP2 is reduced by the TAK1 inhibitor (5Z)-7-oxozeaenol or in TAK1-deficient cells.	5-7-oxo-zeaenol	337-349	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	162-166
12624112-0	2003	A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase.	5-7-oxo-zeaenol	27-42	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	106-110
17172402-7	2006	In addition, pretreatment of cells with 5Z-7-oxozeaenol, a selective TAK1 kinase inhibitor, enhanced the TRAIL-induced cleavage of caspases and binding of Annexin V.	5-7-oxo-zeaenol	40-55	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	69-73
17172402-7	2006	In addition, pretreatment of cells with 5Z-7-oxozeaenol, a selective TAK1 kinase inhibitor, enhanced the TRAIL-induced cleavage of caspases and binding of Annexin V.	5-7-oxo-zeaenol	40-55	TNF superfamily member 10	Homo sapiens	105-110
17172402-7	2006	In addition, pretreatment of cells with 5Z-7-oxozeaenol, a selective TAK1 kinase inhibitor, enhanced the TRAIL-induced cleavage of caspases and binding of Annexin V.	5-7-oxo-zeaenol	40-55	annexin A5	Homo sapiens	155-164
12624112-3	2003	We identified a natural resorcylic lactone of fungal origin, 5Z-7-oxozeaenol, as a highly potent inhibitor of TAK1.	5-7-oxo-zeaenol	61-76	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	110-114
12624112-4	2003	This compound did not effectively inhibit the catalytic activities of the MEKK1 or ASK1 MAPKKKs, suggesting that 5Z-7-oxozeaenol is a selective inhibitor of TAK1.	5-7-oxo-zeaenol	113-128	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	157-161
12624112-5	2003	In cell culture, 5Z-7-oxozeaenol blocked interleukin-1-induced activation of TAK1, JNK/p38 MAPK, IkappaB kinases, and NF-kappaB, resulting in inhibition of cyclooxgenase-2 production.	5-7-oxo-zeaenol	17-32	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	77-81
12624112-5	2003	In cell culture, 5Z-7-oxozeaenol blocked interleukin-1-induced activation of TAK1, JNK/p38 MAPK, IkappaB kinases, and NF-kappaB, resulting in inhibition of cyclooxgenase-2 production.	5-7-oxo-zeaenol	17-32	mitogen-activated protein kinase 8	Homo sapiens	83-86
12624112-5	2003	In cell culture, 5Z-7-oxozeaenol blocked interleukin-1-induced activation of TAK1, JNK/p38 MAPK, IkappaB kinases, and NF-kappaB, resulting in inhibition of cyclooxgenase-2 production.	5-7-oxo-zeaenol	17-32	mitogen-activated protein kinase 14	Homo sapiens	87-90
12624112-5	2003	In cell culture, 5Z-7-oxozeaenol blocked interleukin-1-induced activation of TAK1, JNK/p38 MAPK, IkappaB kinases, and NF-kappaB, resulting in inhibition of cyclooxgenase-2 production.	5-7-oxo-zeaenol	17-32	nuclear factor kappa B subunit 1	Homo sapiens	118-127
12624112-7	2003	Thus, 5Z-7-oxozeaenol blocks proinflammatory signaling by selectively inhibiting TAK1 MAPKKK.	5-7-oxo-zeaenol	6-21	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	81-85
12624112-7	2003	Thus, 5Z-7-oxozeaenol blocks proinflammatory signaling by selectively inhibiting TAK1 MAPKKK.	5-7-oxo-zeaenol	6-21	mitogen-activated protein kinase kinase kinase 4	Homo sapiens	86-92
10606001-0	1999	Inhibition of endotoxin-induced TNF-alpha production in macrophages by 5Z-7-oxo-zeaenol and other fungal resorcylic acid lactones.	5-7-oxo-zeaenol	71-87	tumor necrosis factor	Mus musculus	32-41